[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1175
1. Esteghamati A, Khalilzadeh O, Ashraf H, Zandieh A, Morteza A, Rashidi A, Meysamie A, Nakhjavani M: Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007). Metabolism; 2010 Dec;59(12):1730-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical activity is correlated with serum leptin independent of obesity: results of the national surveillance of risk factors of noncommunicable diseases in Iran (SuRFNCD-2007).
  • Reports on the relationship between leptin and physical activity (PA) at the population level are scarce.
  • The present study examined the relationship between serum leptin concentrations and PA in a nationally representative sample of 3001 Iranian adults aged 25 to 64 years.
  • Serum leptin was measured with an enzyme-linked immunosorbent assay.
  • After adjustment for age, area of residence, smoking, body mass index, and waist circumference, total PA (r = -0.129, P = .038 in men and r = -0.226, P = .006 in women), the duration of vigorous-intensity activity (r = -0.120, P = .044 in men and r = -0.154, P = .019 in women), the duration of moderate-intensity activity (r = -0.114, P = .047 in men and r = -0.160, P = .018 in women), and time spent on sedentary behaviors (r = 0.194, P = .014 in men and r = -0.204, P = .007 in women) were significantly correlated with serum leptin.
  • In both sexes, participants in higher categories of PA had significantly lower serum leptin levels.
  • In conclusion, our results demonstrated an inverse association between leptin concentrations and PA independent of age, sex, smoking, and body adiposity.
  • Our results point to the regulatory effects of PA on serum leptin.
  • [MeSH-major] Exercise. Leptin / blood. Obesity / physiopathology. Population Surveillance

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20580780.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


2. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D'Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P: Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res; 2009 Aug;29(8):3321-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of serum adipokine levels in colorectal cancer patients.
  • BACKGROUND: Adipokines may significantly influence the growth and proliferation of tumor stroma and malignant cells within.
  • Reduced adiponectin and increased leptin serum levels were found in colorectal cancer (CRC) patients.
  • Recently, it has been demonstrated that tumor necrosis factor-alpha (TNF-alpha) is able to induce dose-dependent changes in serum adipokine levels.
  • MATERIALS AND METHODS: Baseline leptin, adiponectin and TNF-alpha levels were analyzed in 90 patients with histologically diagnosed primary or newly diagnosed metastatic CRC treated at 'Tor Vergata' Clinical Center and followed up for a median period of 3 years.
  • RESULTS: Serum leptin levels were higher in CRC patients than in controls (p<0.0001).
  • Conversely, serum adiponectin levels were lower in CRC patients than in controls (p<0.0001).
  • Leptin inversely correlated with adiponectin (p<0.005).
  • The leptin/adiponectin (L/A) ratio was eight-fold greater in CRC compared to controls (p<0.0001).
  • CONCLUSION: Serum adipokine levels might have a role in the biology of CRC and the combined measurement of leptin and adiponectin levels might provide useful prognostic information in the management of patients with CRC.
  • [MeSH-minor] Adiponectin / blood. Adult. Aged. Case-Control Studies. Female. Follow-Up Studies. Humans. Leptin / blood. Male. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Survival Rate. Treatment Outcome. Tumor Necrosis Factor-alpha / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661351.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ADIPOQ protein, human; 0 / Adiponectin; 0 / Leptin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


3. Bhat GK, Plant TM, Mann DR: Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta. Eur J Endocrinol; 2005 Jul;153(1):153-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between serum concentrations of leptin, soluble leptin receptor, testosterone and IGF-I, and growth during the first year of postnatal life in the male rhesus monkey, Macaca mulatta.
  • OBJECTIVES: Subnormal leptin levels in low birth weight infants may allow for catch-up growth during infancy.
  • Scant data are available that relate growth with circulating leptin during normal infancy in primates.
  • The current study objective was to examine the association between serum leptin, its soluble receptor (sOB-R), testosterone and IGF-I concentrations, and body weight during infancy in male rhesus monkeys.
  • DESIGN: Hormone levels were assessed longitudinally in animals (n = 7) from birth until 1 year of age.
  • RESULTS: Body weight increased during the first 6 months of life and was strongly correlated with rising IGF-I levels and, as IGF-I plateaued and then declined during the second half of the year, body weight gain decelerated.
  • In contrast, leptin levels declined gradually with age during the first year of life in conjunction with increasing body weight.
  • There was no association between body weight gain and serum leptin levels or between serum testosterone and leptin values.
  • Since sOB-R levels also declined with leptin values, it does not appear that levels of bioavailable leptin changed during infancy.
  • CONCLUSIONS: The data do not support the contention that leptin regulates growth during infancy, but the close association between IGF-I levels and body weight suggested that this hormone may regulate growth in infant male monkeys.
  • The failure to observe an association between serum testosterone and leptin concentrations suggested that leptin is not involved in the activation of the hypothalamic-pituitary -testicular axis during this developmental period.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994757.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM08248; United States / NICHD NIH HHS / HD / HD08610; United States / NICHD NIH HHS / HD / HD13254; United States / NICHD NIH HHS / HD / HD41749; United States / NCRR NIH HHS / RR / RR03024
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 3XMK78S47O / Testosterone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


Advertisement
4. Kojima M, Sakurai S, Shimizu K, Itoh H: B-cell cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases. Int J Surg Pathol; 2010 Oct;18(5):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell cutaneous lymphoid hyperplasia representing progressive transformation of germinal center: a report of 2 cases.
  • The authors report histomorphologic, immunophenotypic, and genotypic findings of 2 cases of B-cell CLH demonstrating progressive transformation of germinal center (PTGC).
  • PTGC was characterized by enlarged but well-circumscribed follicles without clear demarcation of the germinal center and mantle zone, which contained a predominance of small lymphocytes and variable numbers of centrocytes, centroblasts, and immunoblasts.
  • However, there were no centroblasts and immunoblasts resembling lymphocytic and/or histiocytic Reed-Sternberg cell variants in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in either lesion.
  • These unusual CLHs should be differentiated from the primary cutaneous marginal zone B-cell lymphoma, primary cutaneous follicular lymphoma, particularly "floral variant," or NLPHL.
  • To avoid overdiagnosis and overtreatment, immunophenotypic and genotypic studies are required along with careful morphologic examination.
  • [MeSH-major] B-Lymphocytes / pathology. Cell Transformation, Neoplastic / pathology. Germinal Center / pathology. Pseudolymphoma / pathology. Skin Diseases / pathology
  • [MeSH-minor] Aged. Biomarkers / metabolism. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, Follicular / diagnosis. Male. Middle Aged. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815203.001).
  • [ISSN] 1940-2465
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


5. Grønbaek K, Ralfkiaer U, Dahl C, Hother C, Burns JS, Kassem M, Worm J, Ralfkiaer EM, Knudsen LM, Hokland P, Guldberg P: Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms. Mod Pathol; 2008 May;21(5):632-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent hypermethylation of DBC1 in malignant lymphoproliferative neoplasms.
  • Here, we examined DBC1 at 9q33.1 as a potential target in lymphomagenesis.
  • DBC1 is a putative tumor suppressor that has been shown to be involved in the regulation of cell growth and programmed cell death.
  • DBC1 was hypermethylated in 5 of 5 B-cell-derived lymphoma cell lines, 41 of 42 diffuse large B-cell lymphomas, 24 of 24 follicular lymphomas, 5 of 5 mantle cell lymphomas, 4 of 4 small lymphocytic lymphomas, 1 of 2 lymphoplasmacytoid lymphomas, and in 12 of 12 acute lymphoblastic leukemias, but was unmethylated in 1 case of splenic marginal zone lymphoma, in 12 of 12 multiple myelomas, in 24 of 24 reactive lymph nodes, and in 12 of 12 samples of blood lymphocytes from random donors.
  • DBC1 hypermethylation was associated with transcriptional silencing in lymphoma cell lines, and reexpression of this gene could be induced by treatment with the demethylating agent, 5-aza-2'-deoxycytidine.
  • Our data suggest that hypermethylation of the DBC1 promoter region is a frequent event during the development of lymphoproliferative malignancies, and that DBC1 hypermethylation may serve as a marker for these cancers.
  • [MeSH-minor] Aged. CpG Islands / genetics. DNA, Neoplasm / genetics. Humans. Middle Aged. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264085.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DBC1 protein, human; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


6. Krcmár J, Kotolová H, Veselá L, Csöllei J, Gonec T, Karpísek M, Bartosová L, Necas J: [Study of a newly synthesized substance with a potential to stimulate beta3-adrenergic receptors]. Ceska Slov Farm; 2006 May;55(3):120-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of six-week oral administration of the newly synthesized substance B496 (methyl-4-[2-[2-hydroxy-3-(4-ethylcarbamoyl)phenoxyprophyl]amino]etyl)-phenoxyacetate hydrochloride) on serum glucose, triglycerides, total cholesterol, and leptin levels were studied in male Wistar rats fed with a high-fat diet.
  • The results indicated a significant reduction in serum glucose levels (-26 %, p<0,01), triacylglyceride levels (-21 %, p<0,05) and leptin levels (-43 %, p<0,01).
  • Further the effect of a single intraperitoneal dose (1 mg/kg) of B496 and BRL-37344 on serum leptin levels in the C57Bl/6J mouse was investigated.
  • Administration of BRL-37344 resulted in a significant decrease in serum leptin levels (-55 %, p<0,001).
  • [MeSH-major] Adrenergic beta-Agonists / pharmacology. Leptin / blood. Receptors, Adrenergic, beta-3 / drug effects

  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838489.001).
  • [ISSN] 1210-7816
  • [Journal-full-title] Ceská a Slovenská farmacie : casopis Ceské farmaceutické spolecnosti a Slovenské farmaceutické spolecnosti
  • [ISO-abbreviation] Ceska Slov Farm
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; 0 / B496 compound; 0 / Blood Glucose; 0 / Ethanolamines; 0 / Leptin; 0 / Phenoxyacetates; 0 / Receptors, Adrenergic, beta-3; 0 / Triglycerides; 114333-71-0 / BRL 37344; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


7. Becker DJ, Sevilla DW, O'Connor O: Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus. Acta Haematol; 2010;123(2):77-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus.
  • A patient with chronic hepatitis C virus (HCV) presented to our clinic with a hepatic mass as well as lymphocytosis.
  • Biopsy of the hepatic mass revealed apposed hepatocellular carcinoma (HCC) and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL).
  • Dramatic examples of lymphoma regression during treatment with antiviral medication in chronic HCV patients have suggested an etiologic role for HCV in lymphomagenesis.
  • A growing body of research seeks to clarify the details of the interaction between HCV and B-cell lymphomas.
  • This case of adjacent SLL/CLL and HCC is the first published diagnosis of these two diseases in the liver at one time, and the only published example of the physical apposition of any lymphoma and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Liver Neoplasms / virology
  • [MeSH-minor] Aged. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / diagnosis. Humans. Male


8. Wang X, Yuling H, Yanping J, Xinti T, Yaofang Y, Feng Y, Ruijin X, Li W, Lang C, Jingyi L, Zhiqing T, Jingping O, Bing X, Li Q, Chang AE, Sun Z, Youxin J, Jinquan T: CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells. J Immunol; 2007 Sep 1;179(5):2880-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CCL19 and CXCL13 synergistically regulate interaction between B cell acute lymphocytic leukemia CD23+CD5+ B Cells and CD8+ T cells.
  • However, the interaction between malignant B and T cells remains to be fully elucidated.
  • In a previous study, we have reported that ligation of CCL19-CCR7 and CXCL13-CXCR5 activates paternally expressed gene 10 (PEG10), resulting in an enhancement of apoptotic resistance in B-cell acute lymphocytic leukemia (B-ALL) CD23+CD5+ B cells.
  • Here, we report that B-ALL CD23+CD5+ B cells produce IL-10 at high level, which can be further elevated by costimulation with CCL19 and CXCL13.
  • CCL19/CXCL13-activated B-ALL CD23+CD5+ B cells, in turn, increase IL-10 expression in syngeneic CD8+ T cells in a B cell-derived IL-10-dependent manner and requiring a cell-cell contact.
  • Moreover, using a short hairpin RNA to knockdown PEG10, we provide direct evidence that increased expression of PEG10 in B-ALL CD23+CD5+ B cells is involved in malignant B-T cell interaction, contributing to the up-regulation of IL-10 expression, as well as to the impairment of cytotoxicity of syngeneic CD8+ T cells.
  • Thus, malignant B-ALL CD23+CD5+ B cells play an immunoregulatory role in controlling different inflammatory cytokine expressions.
  • [MeSH-major] B-Lymphocytes / immunology. Burkitt Lymphoma / immunology. CD8-Positive T-Lymphocytes / immunology. Chemokine CCL19 / physiology. Chemokine CXCL13 / physiology. Immunologic Surveillance / immunology
  • [MeSH-minor] Adolescent. Adult. Antigens, CD5 / analysis. Child. Child, Preschool. Cytotoxicity, Immunologic. Female. Humans. Interleukin-10 / metabolism. Male. Middle Aged. Proteins / antagonists & inhibitors. Proteins / genetics. Proteins / metabolism. RNA, Small Interfering / pharmacology. Receptors, IgE / analysis. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Immunol. 2007 Nov 15;179(10):7184
  • (PMID = 17709502.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / CXCL13 protein, human; 0 / Chemokine CCL19; 0 / Chemokine CXCL13; 0 / PEG10 protein, human; 0 / Proteins; 0 / RNA, Small Interfering; 0 / Receptors, IgE; 130068-27-8 / Interleukin-10
  •  go-up   go-down


9. Brown JR: Inherited predisposition to chronic lymphocytic leukemia. Expert Rev Hematol; 2008 Oct;1(1):51-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inherited predisposition to chronic lymphocytic leukemia.
  • Inherited susceptibility to chronic lymphocytic leukemia (CLL) has been recognized for decades.
  • Approximately 10% of individuals with CLL report a family history of CLL or a related lymphoproliferative disorder, and genetic predisposition is the best understood risk factor for CLL.
  • Monoclonal B-cell lymphocytosis (MBL) has been identified recently as a likely precursor to CLL; it is found in the general population with increasing age and enriched in unaffected relatives of individuals with familial CLL.
  • Studies of MBL as well as mouse models of CLL may lead to better understanding of early CLL pathogenesis that is relevant to familial predisposition.
  • To date, the identification of genes that predispose to familial CLL has been slow, primarily due to the relatively few families available for study, the small size of those families and disease causation most likely by multiple genes that each confer smaller risks.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Jul 15;100(2):635-9 [12091358.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1229-32 [12094247.001]
  • [Cites] Leuk Res. 2002 Sep;26(9):791-4 [12127552.001]
  • [Cites] Blood. 2002 Aug 1;100(3):1100-1 [12150154.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2289-90 [12239136.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):107-12 [9136948.001]
  • [Cites] Immunity. 1997 Nov;7(5):703-13 [9390693.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1696-8 [9823943.001]
  • [Cites] Am J Hum Genet. 1999 Jul;65(1):265-9 [10364544.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1497-500 [10516748.001]
  • [Cites] Nat Rev Genet. 2005 Oct;6(10):756-65 [16205715.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Int J Immunogenet. 2006 Feb;33(1):21-4 [16426238.001]
  • [Cites] Leukemia. 2006 Feb;20(2):280-5 [16341048.001]
  • [Cites] Cytometry B Clin Cytom. 2007 Sep;72(5):344-53 [17266153.001]
  • [Cites] Cytogenet Genome Res. 2007;118(1):8-12 [17901694.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2260-6 [17583571.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3326-33 [17687107.001]
  • [Cites] Nat Genet. 2007 Nov;39(11):1315-7 [17934461.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):690-700 [18021083.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):701-8 [18021084.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):724-9 [18021087.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):762-71 [18021089.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):774-9 [18021091.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):645-57 [17941951.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):809-19 [17941952.001]
  • [Cites] Br J Haematol. 2007 Dec;139(5):744-52 [17961188.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5448-57 [17968022.001]
  • [Cites] Nat Genet. 2008 Mar;40(3):281-3 [18264098.001]
  • [Cites] Nat Genet. 2008 May;40(5):631-7 [18372901.001]
  • [Cites] Nat Genet. 2008 May;40(5):623-30 [18372905.001]
  • [Cites] Nat Genet. 2008 May;40(5):616-22 [18385676.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5691-3 [18424666.001]
  • [Cites] N Engl J Med. 2008 Aug 7;359(6):575-83 [18687638.001]
  • [Cites] Leuk Res. 2009 Jan;33(1):162-5 [18556064.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):616-24 [10583268.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1413-9 [10666219.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3028-33 [10716693.001]
  • [Cites] Eur J Haematol. 2000 Aug;65(2):114-7 [10966171.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):395-407 [10983986.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3982-4 [11090088.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2098-104 [11264177.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):203-7 [11291046.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • [Cites] Leuk Lymphoma. 2001 Jun;42(1-2):99-108 [11699227.001]
  • [Cites] Lancet. 2002 Mar 30;359(9312):1114-9 [11943260.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4216-8 [12010828.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60 [12011454.001]
  • [Cites] Blood. 2002 Jul 15;100(2):603-9 [12091354.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):713-5 [12437649.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] Cancer Causes Control. 2002 Nov;13(9):791-5 [12462543.001]
  • [Cites] Leuk Lymphoma. 2002 Oct;43(10):1987-90 [12481897.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Mar;52(1):1-12 [12599176.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):866-73 [12786797.001]
  • [Cites] Leuk Res. 2003 Oct;27(10):973-5 [12860021.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2337-42 [14630808.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2424-33 [15059895.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):673-82 [15126604.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1162-3 [15085160.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):1065-7 [15184265.001]
  • [Cites] Semin Hematol. 2004 Jul;41(3):201-6 [15269880.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1850-4 [15161669.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):399-408 [15488762.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] Leuk Res. 1991;15(5):305-14 [2046383.001]
  • [Cites] Cancer Res. 1992 Jan 15;52(2):437-43 [1370214.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12530-4 [7809072.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Am J Hum Genet. 1996 Nov;59(5):990-8 [8900225.001]
  • [Cites] Leuk Res. 2005 Jan;29(1):59-61 [15541476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16600-5 [15545599.001]
  • [Cites] N Engl J Med. 2005 Apr 21;352(16):1667-76 [15843669.001]
  • [Cites] Cancer. 2005 May 1;103(9):1906-15 [15779016.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1245-50 [15894680.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1025-8 [15800670.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1088-9; author reply 1093-5 [16030308.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1089-90; author reply 1093-5 [16030309.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1090-1; author reply 1093-5 [16030310.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1091-2; author reply 1093-5 [16030311.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1092-3; author reply 1093-5 [16030312.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):325-32 [16042682.001]
  • [Cites] Am J Hum Genet. 2005 Sep;77(3):420-9 [16080117.001]
  • [Cites] J Immunol. 2005 Oct 1;175(7):4309-19 [16177071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1466-74 [16204696.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1831-5 [16217763.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):983-7 [16432079.001]
  • [Cites] Br J Haematol. 2006 Apr;133(1):59-61 [16512829.001]
  • [Cites] Leukemia. 2006 Apr;20(4):728-9 [16437141.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):195-201 [16616066.001]
  • [Cites] Nat Genet. 2006 Jun;38(6):659-62 [16715099.001]
  • [Cites] Blood. 2006 Jul 15;108(2):638-44 [16574953.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1117-20 [16885053.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1334-8 [16670263.001]
  • [Cites] Leuk Res. 2006 Dec;30(12):1573-6 [16581122.001]
  • [Cites] Blood. 2007 Feb 1;109(3):916-25 [17047154.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1202-10 [17053054.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Br J Haematol. 2007 Apr;137(2):173-5 [17391501.001]
  • [Cites] Nat Genet. 2007 May;39(5):645-9 [17401363.001]
  • [Cites] Nat Genet. 2007 May;39(5):631-7 [17401366.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5079-86 [17351108.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1087-91 [17577771.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):977-83 [17603485.001]
  • [Cites] Nat Genet. 2007 Aug;39(8):984-8 [17618284.001]
  • (PMID = 19802369.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA115682-03; United States / NCI NIH HHS / CA / K23 CA115682-04; None / None / / K23 CA115682-03; United States / NCI NIH HHS / CA / CA115682-01; United States / NCI NIH HHS / CA / K23 CA115682; United States / NCI NIH HHS / CA / CA115682-04; United States / NCI NIH HHS / CA / K23 CA115682-01; United States / NCI NIH HHS / CA / CA115682-02; United States / NCI NIH HHS / CA / K23 CA115682-02
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Keywords] NOTNLM ; association / familial chronic lymphocytic leukemia / linkage / lymphocytosis / monoclonal B cell
  •  go-up   go-down


10. Jose VJ, Mariappan P, George PV, Selvakumar, Selvakumar D: Serum leptin levels in acute myocardial infarction. Indian Heart J; 2005 Jan-Feb;57(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in acute myocardial infarction.
  • BACKGROUND: Several studies have shown an association of serum leptin levels with cardiovascular diseases.
  • The present study was undertaken to assess levels of serum leptin in patients presenting with acute ST segment elevation myocardial infarction.
  • The serum leptin levels in patients with myocardial infarction was 6.51 +/- 6.76 ng/ml versus 2.86 +/- 2.22 ng/ml in controls.
  • In the multivariate analysis the odds ratio for serum leptin with myocardial infarction was 1.45 with a 95% confidence interval of 1.2 to 1.8.
  • CONCLUSIONS: Our results suggest that serum leptin level is elevated in patients with acute ST segment elevation myocardial infarction.
  • [MeSH-major] Leptin / blood. Myocardial Infarction / blood

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852893.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


11. Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G: Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma; 2010 Aug;51(8):1485-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.
  • The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL).
  • Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m(2) on day 1 and cladribine 0.1 mg/kg subcutaneously on days 2-6.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578816.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Equilibrative Nucleoside Transporter 1; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


12. Xiao C, Su ZL, Wu QL, Gao HY, Fang JC, Xia ZJ, Guan ZZ: [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Jan;34(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and pathological reassessment of 493 cases of non-Hodgkin's lymphomas according to current WHO classification of lymphoid neoplasms].
  • OBJECTIVE: To investigate the clinical and pathological features of non-Hodgkin's lymphoma (NHL) and to evaluate the applicability of the new WHO classification of lymphoid neoplasms.
  • METHODS: According to the new WHO classification, a total of 500 cases of non-Hodgkin's lymphoma diagnosed during the period 1992 - 2003 were reviewed and reappraised with their morphological, immunological and clinical characteristics.
  • RESULTS: Among 500 cases previously diagnosed as lymphomas, 493 cases (98.6%) were confirmed to be NHL, of which B-cell neoplasms was 69.0% and T/NK-cell neoplasms 29.8%.
  • Overall, 6 subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), unspecified peripheral T-cell lymphoma (PT-un), precursor T-lymphoblastic lymphoma (T-LBL), extranodal marginal zone B-cell lymphoma of MALT type (MALT) and B-small lymphocytic lymphoma (B-SLL) were among the most common subtypes.
  • In pediatric and young patient populations, the most common subtypes were LBL, DLBCL and Burkitt's lymphoma.
  • Marginal zone B-cell lymphoma and SLL demonstrated the best prognosis, LBL and PT-un both the worst, whereas DLBCL and FL had an intermediate prognosis, however, subgrouping of FL according to WHO classification did not reveal a significant survival difference (P > 0.05).
  • CONCLUSIONS: Basing upon the results of a comprehensive survey on the morphologic features, immunophenotyping and clinical data of the above cases, the new WHO classification of lymphoid neoplasms is practical and easily applicable for routine pathological evaluation of lymphoproliferaive disorders and in guiding the clinical management.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / epidemiology. Burkitt Lymphoma / pathology. Child. Child, Preschool. China / epidemiology. Female. Humans. Killer Cells, Natural. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / classification. Lymphoma, Follicular / epidemiology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / epidemiology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796877.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


13. Teixeira PF, Cabral MD, Silva NA, Soares DV, Braulio VB, Couto AP, Henriques JL, Costa AJ, Buescu A, Vaisman M: Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition. Thyroid; 2009 May;19(5):443-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin in overt and subclinical hypothyroidism: effect of levothyroxine treatment and relationship to menopausal status and body composition.
  • BACKGROUND: The relationship between thyroid status, including subclinical hypothyroidism (SH) and serum leptin is controversial or uncertain.
  • Therefore we evaluated serum leptin in SH and overt hypothyroidism (OH) and determined the effects of levothyroxine (LT(4)) replacement on serum leptin in these disorders.
  • METHODS: Serum leptin, thyrotropin (TSH), free thyroxine, insulin, glucose, and body composition parameters were compared in 55 SH, 20 OH, and 28 euthyroid (EU) pre- and postmenopausal women.
  • In addition, the effect of LT(4) treatment on serum leptin in SH and OH was assessed.
  • RESULTS: The mean +/- SD (median) serum leptin concentrations in the OH and SH groups were higher than in the EU group (35.1 +/- 27.2 [33.0] and 36.6 +/- 21.9 [30.6] ng/mL, respectively, vs. 23.2 +/- 19.3 [17.9] ng/mL, p = 0.011), but the difference was only significant in postmenopausal women.
  • In premenopausal women there was no correlation between leptin, BMI, or FMI and serum TSH levels (r(s) = 0.009, p = 0.474; r(s) = 0.043, p = 0.367; r(s) = 0.092, p = 0.232).
  • In the postmenopausal women, the partial correlation coefficient between TSH and leptin was present, even when controlling for BMI (r(s) = 0.297, p = 0.042) and FMI (r(s) = 0.275, p = 0.050).
  • LT(4) treatment was associated with a reduction of serum leptin concentrations in the OH group (p = 0.008).
  • In SH group there were no differences between LT(4) replacement or no treatment, since a fall in serum leptin levels was detected in both SH subgroups, despite a more pronounced fall with LT(4) use.
  • CONCLUSIONS: Serum leptin concentrations are elevated in postmenopausal women with SH or OH.
  • A relationship between thyroid status and serum leptin is further supported by the fact that LT(4) treatment, to restore the EU status, reduced serum leptin levels in OH in the absence of significant effects on BMI.
  • In women, hypothyroidism influences either leptin secretion or degradation and this effect is more pronounced in postmenopausal than in premenopausal women.
  • [MeSH-major] Body Composition. Hormone Replacement Therapy. Hypothyroidism / drug therapy. Leptin / blood. Postmenopause / blood. Premenopause / blood. Thyroxine / therapeutic use

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415994.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


14. Oumeish OY, Oumeish I, Tarawneh M, Salman T, Sharaiha A: Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature. Int J Dermatol; 2006 Mar;45(3):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Necrobiotic xanthogranuloma associated with paraproteinemia and non-Hodgkin's lymphoma developing into chronic lymphocytic leukemia: the first case reported in the literature and review of the literature.
  • A 56-year-old married female presented in May 1998 with a 5-month history of xanthelasma of the eyelids, followed 4 months later by two enlarged lymph nodes of the left side of the neck and three of the left axilla.
  • In July 1998, computed tomography (CT) scans of the chest and abdomen with contrast medium showed pretracheal, bilateral axillary, right retrochural, paracaval, aortocaval, and para-aortic lymph node enlargement.
  • These findings were suggestive of lymphoma.
  • One cervical and two left axillary lymph nodes were excised.
  • They revealed total replacement of the nodular architecture by a diffuse proliferation of mature lymphoid cells having small nuclei and a crumbled chromatin pattern, and very rare mitosis.
  • It was concluded from the lymph node biopsies that these changes were typical of non-Hodgkin's lymphoma, diffuse and small cell type, of low-grade malignancy.
  • The bone marrow picture was consistent with diffuse, well-differentiated non-Hodgkin's lymphoma, developing into chronic lymphocytic leukemia (CLL).
  • Endoscopy showed antral-type gastric mucosa exhibiting mild chronic gastritis.
  • Skin biopsy from a fresh lesion on the back showed a diffuse inflammatory cell infiltrate with collections of histiocytic cells.
  • The blood picture also showed monoclonal IgG paraprotein (3170 mg/dL) of the kappa light chain type.
  • The patient was treated by the oncologist for her lymphoma, and was given Cytoxan, prednisolone, endoxan, Leukeran, and melphalan.
  • She also responded to Leukeran at a dose of 5 mg daily for 5 days every month for 6 months, and showed regression in the size of the lymph nodes.
  • [MeSH-major] Granuloma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Lymphoma, Non-Hodgkin / complications. Necrobiotic Disorders / pathology. Paraproteinemias / etiology. Xanthomatosis / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Xanthogranuloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533236.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Glucocorticoids; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan
  •  go-up   go-down


15. Gadzinowski J, Kowalska K, Vidyasagar D: Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO. J Perinatol; 2008 Dec;28 Suppl 3:S56-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of MAS with PPHN using combined therapy: SLL, bolus surfactant and iNO.
  • In this study, thirteen infants with diagnosis of MAS and PPHN were first treated with conventional respiratory support.
  • Then between 2 and 22h of life they were randomized either to bolus surfactant treatment (n=6) or surfactant lung lavage (SLL, n=7) treatment.
  • The results showed that infants treated with SLL had significant improvements in oxygenation, decreases in MAP and A-a gradients.
  • In conclusion these data show no advantage of SLL therapy over bolus surfactant treatment in infants with MAS complicated by PPHN.

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19057612.001).
  • [ISSN] 1476-5543
  • [Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association
  • [ISO-abbreviation] J Perinatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pulmonary Surfactants; 31C4KY9ESH / Nitric Oxide
  •  go-up   go-down


16. Holland-Cunz S, Göppl M, Rauch U, Bär C, Klotz M, Schäfer KH: Acquired intestinal aganglionosis after a lytic infection with varicella-zoster virus. J Pediatr Surg; 2006 Mar;41(3):e29-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She underwent multiple laparotomies in which histological sections of the entire small intestine could be obtained.
  • A more detailed immunohistochemical analysis using neuronal (PGP, enolase), glial (S100), and lymphocytic (LCA) antibodies demonstrated a nearly complete neuronal loss.
  • [MeSH-major] Enteric Nervous System / pathology. Enteric Nervous System / virology. Herpes Zoster / complications. Intestinal Diseases / etiology. Intestine, Small / innervation
  • [MeSH-minor] Child, Preschool. Female. Humans. Ileus / etiology. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516611.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Aldoss IT, Blumel SM, Bierman PJ: The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Manag Res; 2009;1:155-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma.
  • There is no consensus on recommendations for the treatment of relapsed and refractory indolent non-Hodgkin lymphoma (NHL).
  • This agent has a high degree of activity against a variety of tumor cell lines.
  • Clinically, bendamustine has demonstrated activity against indolent NHL, chronic lymphocytic lymphoma, multiple myeloma and mantle cell lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):871-7 [16096436.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):812-26 [19103723.001]
  • [Cites] Ther Clin Risk Manag. 2008 Aug;4(4):727-32 [19209254.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Biochim Biophys Acta. 1972 Dec 22;287(3):386-9 [4629776.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):12-4 [12170426.001]
  • [Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]
  • [Cites] J Clin Oncol. 2002 Aug 1;20(15):3262-9 [12149300.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12 [16402269.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4143-9 [16896003.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):759-70 [16957931.001]
  • [Cites] Anticancer Drugs. 2007 Jun;18(5):587-95 [17414628.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2316-23 [17597807.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1299-306 [17613757.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53 [17653574.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 1:S13-7 [18282361.001]
  • [Cites] Blood. 2008 Jul 15;112(2):330-9 [18451308.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Feb;135(2):227-34 [18719942.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2596-7 [18809766.001]
  • [Cites] Anticancer Drugs. 1996 Jun;7(4):415-21 [8826610.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Pharmazie. 1985 Nov;40(11):782-4 [4095129.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Nov;128(11):603-9 [12458340.001]
  • [Cites] Semin Oncol. 2002 Aug;29(4 Suppl 13):4-11 [12170425.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1417-23 [15494430.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3383-9 [15908650.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12 [16088404.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7565-73 [16186600.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7985-93 [16204016.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Feb;132(2):99-104 [16292542.001]
  • [Cites] Br J Cancer. 2007 Jun 4;96(11):1692-8 [17486132.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):211-7 [18056679.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):309-17 [18172283.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):204-10 [18182663.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2096-105 [12357363.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1821-7 [15223642.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):911-3 [15291348.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2445-9 [15621757.001]
  • [Cites] Haematologica. 2001 May;86(5):485-93 [11410411.001]
  • [Cites] Anticancer Drugs. 2001 Oct;12(9):725-9 [11593053.001]
  • [Cites] Haematologica. 2002 Jan;87(1):33-43 [11801463.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):327-31 [11999564.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 May;128(5):271-8 [12029443.001]
  • [Cites] Blood. 2008 Dec 15;112(13):4824-31 [18799723.001]
  • (PMID = 21188134.001).
  • [ISSN] 1179-1322
  • [Journal-full-title] Cancer management and research
  • [ISO-abbreviation] Cancer Manag Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3004665
  • [Keywords] NOTNLM ; Treanda / alkylating agent / bendamustine / chronic lymphocytic lymphoma / indolent non-Hodgkin lymphoma
  •  go-up   go-down


18. Dey P, Amir T, Al Jassar A, Al Shemmari S, Jogai S, Bhat M G, Al Quallaf A, Al Shammari Z: Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma. Cytojournal; 2006;3:24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma.
  • AIMS AND OBJECTIVES: In this present study we have evaluated the feasibility of sub-classification of non-Hodgkin's lymphoma (NHL) cases according to World Health Organization's (WHO) classification on fine needle aspiration cytology (FNAC) material along with flow cytometric immunotyping (FCI) as an adjunct.
  • Both cytologic findings and FCI data were interpreted together to diagnose and sub-classify NHL according to WHO classification.
  • The cases were classified on FNAC as predominant small cells (12), mixed small and large cells (5) and large cells (26).
  • In five cases a suggestion of NHL was offered on FNAC material and these cases were labeled as NHL not otherwise specified (NHL-NOS).
  • With the help of combined FCI and FNAC, it was possible to sub-classify 38 cases of NHL (79%) according to WHO classification.
  • Combined FNAC and FCI data helped to diagnose 9 cases of small lymphocytic lymphoma (SLL), 2 cases of mantle cell lymphoma (MCL), 4 cases of follicular lymphoma (FL), 17 cases of diffuse large B lymphoma (DLBL) and 6 cases of lymphoblastic lymphoma.
  • Histopathology diagnosis was available in 31 cases of NHL out of which there were 14 recurrent and 17 cases of primary NHL.
  • Out of 15 DLBL cases diagnosed on FCI and FNAC, histology confirmed 14 cases and one of these cases was diagnosed as Burkitt's lymphoma on histology.
  • Cases of FL (4), SLL (3) and MCL (2) were well correlated with histopathology.
  • Histology diagnosis was given as DLBL (1), SLL (1), anaplastic large cell lymphoma (1) and FL transformed into large cell NHL (1).
  • Considering histopathology as gold standard, diagnostic specificity of combined FNAC and FCI was 100% (31/31) and sensitivity in sub-classification was 83.8% (26/31).
  • CONCLUSION: FNAC combined with FCI may be helpful in accurately sub-classifying NHL according to WHO classification.
  • Many of the subtypes of NHL such as FL and MCL which were previously recognized as a pure morphologic entity can be diagnosed by combined use of FNAC and FCI.
  • Other ancillary investigations such as chromosomal changes, cell proliferation markers etc. may be helpful in this aspect.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1998 Oct;19(4):274-8 [9784991.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):451-7 [10911803.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1792-9 [11100059.001]
  • [Cites] Diagn Cytopathol. 2001 Apr;24(4):229-32 [11285616.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):251-6 [11933272.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):340-2 [12451563.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]
  • [Cites] Diagn Cytopathol. 1992;8(5):551-2 [1396035.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):432-42 [16222688.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):352-7 [8982596.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1771-9 [8781434.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):72-7 [2293872.001]
  • [Cites] Cytopathology. 2006 Oct;17(5):275-87 [16961657.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):329-36 [2343687.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):337-45 [6587711.001]
  • [Cites] Diagn Cytopathol. 1995 May;12(3):201-7 [7621714.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):745-6 [8362592.001]
  • [Cites] Histopathology. 1994 Dec;25(6):517-36 [7698729.001]
  • (PMID = 17069647.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1634871
  •  go-up   go-down


19. Vassallo J, Bousquet M, Quelen C, Al Saati T, Delsol G, Brousset P: CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma. J Clin Pathol; 2007 May;60(5):573-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive diffuse large B cell lymphoma arising from a CD5-positive follicular lymphoma.
  • Follicular lymphoma (FL) is a neoplasm originating from germinal centre cells, corresponding to 25-40% of non-Hodgkin's lymphomas.
  • Transformation into diffuse large B cell lymphoma (DLBCL) occurs in about one-third of cases.
  • CD5 is expressed in B-chronic lymphoid leukaemia/small lymphocytic lymphoma and mantle cell lymphoma, but can rarely be expressed in conjunction with CD10 in well-documented cases of FL.
  • In this report one case of grade 1 FL is described, which transformed into a DLBCL 6 months after initial diagnosis, with both tumours expressing CD5.
  • [MeSH-major] Antigens, CD5 / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antigens, Neoplasm / metabolism. Disease Progression. Female. Humans

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):1-11 [10937042.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):182-90 [16040287.001]
  • [Cites] Am J Clin Pathol. 2000 Dec;114(6):912-21 [11338480.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jul;125(7):951-3 [11419985.001]
  • [Cites] Am J Clin Pathol. 2002 Feb;117(2):291-300 [11863226.001]
  • [Cites] Am J Clin Pathol. 2002 Oct;118(4):589-98 [12375647.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):218-30 [12579992.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2105-11 [15313456.001]
  • [Cites] J Clin Pathol. 1992 Nov;45(11):1018-22 [1280654.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 1996 Sep;94(4):676-84 [8826892.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):16-21 [9059349.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1587-94 [9193357.001]
  • [Cites] Mol Pathol. 1998 Dec;51(6):333-8 [10193514.001]
  • [Cites] Mod Pathol. 2000 Dec;13(12):1269-79 [11144922.001]
  • (PMID = 17513519.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Antigens, Neoplasm
  • [Other-IDs] NLM/ PMC1994527
  •  go-up   go-down


20. Lurie DM, Milner RJ, Suter SE, Vernau W: Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed. Vet Immunol Immunopathol; 2008 Sep 15;125(1-2):102-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic and cytomorphologic subclassification of T-cell lymphoma in the boxer breed.
  • The boxer breed is at high risk for developing lymphoma and, in contrast to the general canine population, is predisposed to the T-cell variant of the disease.
  • The purpose of this study was to more accurately classify lymphoma in this breed.
  • Clinical, cytomorphologic and immunophenotypic data were examined in 43 boxers with lymphoma.
  • Lymphomas were classified as multicentric (n=29), mediastinal (n=6) and intestinal (n=8).
  • Of the 40 immunophenotyped samples, 34 (85%) were T-cell, 5 (12.5%) were B-cell and 1 was a non-B-cell non-T-cell lymphoma.
  • Immunophenotypic subtyping was done on prospectively collected T-cell lymphoma samples (n=22) to differentiate CD4 (helper) from CD8 (cytotoxic) T-cell origin as well as to determine the T-cell receptor (TCR) expression (TCRalphabeta vs. TCRdeltagamma).
  • Cytomorphologic analysis was done on the same 22 samples using the World Health Organization (WHO) classification scheme.
  • According to this scheme, 17/22 samples were classified as lymphoblastic, 2/22 as large cell peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), 2/22 as large granular lymphoma (LGL) high-grade and 1/22 as small lymphocytic.
  • The results of this study indicate that lymphoma in the boxer breed is a disease comprised predominantly of TCRalphabeta+, CD4+ (helper) T-cells with lymphoblastic (high-grade) morphology.
  • [MeSH-major] Dog Diseases / classification. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / veterinary
  • [MeSH-minor] Animals. Antigens, CD4 / blood. Antigens, CD4 / immunology. Antigens, CD8 / blood. Antigens, CD8 / immunology. Biopsy, Fine-Needle / veterinary. Dogs. Female. Genetic Predisposition to Disease. Immunohistochemistry / veterinary. Immunophenotyping / veterinary. Kaplan-Meier Estimate. Male. Prospective Studies. Receptors, Antigen, T-Cell, alpha-beta / blood. Receptors, Antigen, T-Cell, alpha-beta / immunology. Receptors, Antigen, T-Cell, gamma-delta / blood. Receptors, Antigen, T-Cell, gamma-delta / immunology. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579219.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


21. Jahan S, Zinnat R, Hassan Z, Biswas KB, Habib SH: Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers. Int J Diabetes Dev Ctries; 2009 Oct;29(4):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in serum leptin concentrations from umbilical cord blood of newborn infants born to nondiabetic, gestational diabetic and type-2 diabetic mothers.
  • To investigate gender differences, if any, in leptin concentrations from umbilical cord blood of new born infants of mothers with type 2 diabetes mellitus (DM), gestational diabetes mellitus (GDM), and Non diabetic (ND) at delivery.
  • Serum leptin concentrations were measured in 105 newborns (53 males and 52 females in the three groups).
  • Pearson correlation coefficient was used to explore the relationship between serum leptin concentrations and anthropometric measures of the fetus and their mother.
  • Both Serum leptin level and serum C-peptide was measured by chemiluminescence based ELISA.
  • The median range of leptin concentration in cord blood was ND group: Male [13.91 (3.22 - 47.63)], Female [16.88 (2 - 43.65)]; GDM group: Male [32 (7 - 76.00)], Female [36.73 (4.80 - 81.20)]; DM group: Male [20.90 (2 -76.00)], Female [32 {2.58 - 80.67)].
  • Cord serum leptin levels correlated with birth weight(r=0.587, p=0.0001), ponderal index (PI) (r=.319, p=0.024)of the babies and body mass index (BMI) (r=-0.299, p=0.035) of their mothers but did not correlate with gestational age, cord serum C-peptide concentration or placental weight at delivery.
  • Leptin concentrations were higher in the female fetus in comparison to the male fetus.
  • We found that there are very strong associations between cord leptin concentrations at delivery and birth weight, ponderal index of the baby, body mass index of the mothers with Type 2 DM.
  • We also found that high leptin levels could represent an important feedback modulator of substrate supply and subsequently for adipose tissue status during late gestation or adipose tissue is the major determinant of circulating leptin levels.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1995 Sep 25;214(3):1260-7 [7575539.001]
  • [Cites] Eur J Endocrinol. 2001 Jul;145(1):53-8 [11415852.001]
  • [Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]
  • [Cites] Nat Med. 1996 Sep;2(9):949-50 [8782440.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1293-300 [9100610.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1642-4 [9141565.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Sep;82(9):2849-55 [9284709.001]
  • [Cites] Eur J Endocrinol. 1997 Dec;137(6):655-8 [9437232.001]
  • [Cites] Diabetes. 1998 May;47(5):847-50 [9588462.001]
  • [Cites] Science. 1995 Jul 28;269(5223):540-3 [7624776.001]
  • (PMID = 20336197.001).
  • [ISSN] 1998-3832
  • [Journal-full-title] International journal of diabetes in developing countries
  • [ISO-abbreviation] Int J Diabetes Dev Ctries
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2839129
  • [Keywords] NOTNLM ; Newborn infants / Serum leptin / Type 2 Diabetic / Umbilical cord blood / gestational diabetes mellitus / non diabetic
  •  go-up   go-down


22. Kojima M, Yamanaka S, Yoshida T, Shimizu K, Murayama K, Ohno Y, Itoh H, Motoori T, Masawa N, Nakamura S: Histological variety of floral variant of follicular lymphoma. APMIS; 2006 Sep;114(9):626-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological variety of floral variant of follicular lymphoma.
  • To further clarify the histopathological findings of the floral variant of follicular lymphoma (FVFL), we studied 13 Japanese cases.
  • Two histological subtypes of neoplastic follicles of FVFL have been described: (i) A macrogerminal center pattern where the mantle zone lymphocytes were invaginated into the neoplastic germinal center, often reminiscent of a floral design. (ii) A microgerminal center pattern where the massive invasion of mantle zone lymphocytes resulted in almost complete breakage of the neoplastic follicles.
  • In the former pattern, the neoplastic germinal center usually contained large clusters of tumor cells, whereas in the latter, small clusters of up to 20 tumor cells or isolated tumor cells were observed in the neoplastic germinal centers.
  • Moreover, occasional tumor cells showed a lymphocytic and/or histiocytic Reed-Sternberg cell (L&H cells)-like morphology.
  • The overall histological findings of the macrogerminal center are similar to those of florid progressive transformation of germinal center (PTGC), whilst the microgerminal center pattern is similar to that of nodular lymphocyte-predominant Hodgkin lymphoma.
  • Initially, the differential diagnosis between FVFL and florid PTGC was emphasized.
  • However, the present study indicates that nodal marginal zone B-cell lymphoma possessing floral follicles and nodular lymphocyte-predominant Hodgkin lymphoma should be added to the differential diagnosis of FVFL.
  • The germinal center B-cell nature of FVFL is most clearly recognizable by immunohistochemistry, though histological appearance alone may cause some diagnostic problems.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, Follicular / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Diagnosis, Differential. Female. Germinal Center / pathology. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / pathology. Humans. In Situ Hybridization. Male. Middle Aged. Oligonucleotides. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948815.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Oligonucleotides; 0 / RNA, Viral
  •  go-up   go-down


23. El-Ferzli GT, Philips JB 3rd, Bulger A, Ambalavanan N: A pumpless lung assist device reduces mechanical ventilation-induced lung injury in juvenile piglets. Pediatr Res; 2009 Dec;66(6):671-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective is to test the effect of the LAD on pulmonary histopathology in juvenile piglets with acute lung injury caused by saline lung lavage (SLL) followed by intermittent mandatory ventilation (IMV).
  • Three- to 4-wk-old piglets were randomized to no intervention (control group), SLL alone (SLL group), SLL + IMV (IMV group), or SLL + IMV + LAD (LAD group) (n = 6 per group).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1989 Oct;96(4):849-51 [2676391.001]
  • [Cites] Early Hum Dev. 2008 Nov;84(11):709-16 [18930613.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 May;105(5):823-32 [7683735.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Mar;107(3):838-48; discussion 848-9 [8127113.001]
  • [Cites] J Pediatr. 1994 Jul;125(1):104-10 [7517446.001]
  • [Cites] Perfusion. 1994;9(4):265-9 [7981464.001]
  • [Cites] J Paediatr Child Health. 1995 Apr;31(2):105-11 [7794609.001]
  • [Cites] Anesthesiology. 1995 Oct;83(4):710-20 [7574050.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):109-17 [8551400.001]
  • [Cites] ASAIO J. 1994 Jul-Sep;40(3):M728-31 [8555610.001]
  • [Cites] Lancet. 1996 Jul 13;348(9020):75-82 [8676720.001]
  • [Cites] Pediatr Pulmonol. 1996 Oct;22(4):263-70 [8905887.001]
  • [Cites] J Paediatr Child Health. 1997 Jun;33(3):202-8 [9259293.001]
  • [Cites] Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1058-65 [9351603.001]
  • [Cites] ASAIO J. 1997 Sep-Oct;43(5):M821-4 [9360161.001]
  • [Cites] Pediatr Pulmonol Suppl. 1997;16:51 [9443195.001]
  • [Cites] Ann Thorac Surg. 2000 Feb;69(2):351-6 [10735662.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1301-8 [10793162.001]
  • [Cites] Intensive Care Med. 2000 Sep;26(9):1334-42 [11089761.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):542-51 [11241090.001]
  • [Cites] Biol Neonate. 2001 Jul;80(1):74-80 [11474154.001]
  • [Cites] Ann Thorac Surg. 2001 Sep;72(3):899-904 [11570380.001]
  • [Cites] ASAIO J. 2001 Sep-Oct;47(5):486-91 [11575823.001]
  • [Cites] J Pediatr. 2001 Oct;139(4):478-86 [11598592.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1154-60 [11673202.001]
  • [Cites] Pediatr Res. 2002 Sep;52(3):387-92 [12193673.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):1011-6; discussion 1017-8 [12400738.001]
  • [Cites] Pediatr Res. 2003 Feb;53(2):245-53 [12538782.001]
  • [Cites] Crit Care Med. 2003 Mar;31(3):885-92 [12627001.001]
  • [Cites] Eur Respir J Suppl. 2003 Aug;42:2s-9s [12945994.001]
  • [Cites] Respir Physiol Neurobiol. 2004 Jan 15;139(2):167-77 [15123000.001]
  • [Cites] Anesthesiology. 2004 Sep;101(3):722-8 [15329597.001]
  • [Cites] Minerva Pediatr. 2004 Aug;56(4):373-80 [15457135.001]
  • [Cites] JAMA. 1986 Aug 15;256(7):881-6 [3090285.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jan;157(1):294-323 [9445314.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1332-47 [9563759.001]
  • [Cites] J Pharmacol Toxicol Methods. 1998 Aug;40(2):101-7 [10100499.001]
  • [Cites] Clin Chest Med. 2006 Dec;27(4):601-13; abstract viii [17085249.001]
  • [Cites] Clin Physiol Funct Imaging. 2007 Mar;27(2):67-90 [17309528.001]
  • [Cites] J Pediatr. 2007 Jul;151(1):10-5 [17586183.001]
  • [Cites] Neonatology. 2007;92(1):19-25 [17596733.001]
  • [Cites] Intensive Care Med. 2007 Aug;33(8):1423-33 [17563879.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Sep 15;176(6):575-81 [17641159.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1):183-7 [18090370.001]
  • [Cites] Int J Mol Med. 2008 Apr;21(4):513-9 [18360698.001]
  • [Cites] J Perinatol. 2008 May;28 Suppl 1:S47-56 [18446178.001]
  • [Cites] Ann Thorac Surg. 2008 Aug;86(2):410-7; discussion 417 [18640306.001]
  • [Cites] BMC Pulm Med. 2008;8:10 [18625067.001]
  • [Cites] J Pediatr Surg. 1992 Jan;27(1):40-3 [1552442.001]
  • (PMID = 19687779.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD046513-02; United States / NICHD NIH HHS / HD / K08 HD046513; United States / NHLBI NIH HHS / HL / R01 HL092906; United States / NICHD NIH HHS / HD / K08 HD046513-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS149422; NLM/ PMC2796292
  •  go-up   go-down


24. McElroy C, Velilla R, Chaudhary H, Al-Abbadi MA: Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature. Diagn Cytopathol; 2009 Jan;37(1):48-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.
  • Diagnosis of two distinct malignant entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.
  • Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.
  • Co-occurrence of some carcinomas such as squamous cell carcinoma (SCC), may show especially aggressive behavior.
  • A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and diffuse lymphadenopathy of the axillary and cervical regions.
  • FNA of a large cervical lymph node was diagnostic for both atypical lymphocytic proliferation and SCC.
  • Flow cytometric analysis showed the atypical lymphocytic proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.
  • These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-cell SLL/CLL.
  • We report a rare occurrence of metastatic SCC to a lymph node infiltrated by SLL/CLL.
  • The diagnosis was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of cell block material, and flow cytometry on the sample obtained by FNA.
  • To the best of our knowledge, only three cases of SCC metastasis to SLL/CLL diagnosed by FNA have been reported in the English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Neoplasms, Multiple Primary / diagnosis. Oropharyngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973126.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


25. Wang YH, Huang TS, Liang HW, Su TC, Chen SY, Wang TD: Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury. Arch Phys Med Rehabil; 2005 Oct;86(10):1964-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fasting serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury.
  • OBJECTIVES: To measure serum levels of adiponectin, ghrelin, and leptin in men with spinal cord injury (SCI) and to investigate possible correlations between these serum levels and various factors, such as body mass index (BMI), age, injury level, and duration of injury.
  • MAIN OUTCOME MEASURES: Serum levels of adiponectin, ghrelin, and leptin and BMI.
  • RESULTS: Serum leptin levels in subjects with SCI (mean, 7.0+/-0.5 mg/mL) [corrected] were significantly higher than those in able-bodied controls (mean, 4.7+/-0.6 mg/mL) [corrected] (P<.01).
  • The group with tetraplegia had higher serum leptin levels than the group with paraplegia, but this did not reach a statistically significant level (8.2+/-1.1 ng/mL vs 6.4+/-0.5 mg/mL [corrected] P=.097).
  • There were significant differences in serum leptin levels among the 3 groups by 1-way analysis of variance (P=.008).
  • Serum adiponectin levels in subjects with SCI (7.1+/-0.5 mg/mL) [corrected] were higher than those in able-bodied controls (5.6+/-0.5 mg/mL) [corrected] but this was not statistically significant (P=.08).
  • In contrast, serum levels of ghrelin in subjects with SCI (302.0+/-17.5 pg/mL) were similar to those in the controls (264.0+/-27.0 pg/mL) (P=.24).
  • Serum leptin levels correlated positively with BMI (SCI, r=.698, P<.001; controls, r=.782, P<.001), whereas serum adiponectin (SCI, r=-.527, P<.001; controls, r=-.315, P=.057) and ghrelin (SCI, r=-.368, P<.001; controls, r=-.447, P=.006) levels correlated negatively with the BMI in both subjects with SCI and controls.
  • CONCLUSIONS: Men with SCI have significantly higher serum leptin levels than able-bodied controls, and serum leptin levels correlated with the degree of neurologic deficit.
  • Men with SCI had a tendency toward higher serum adiponectin level than able-bodied controls.
  • Serum levels of ghrelin in men with SCI were similar to those of controls.
  • [MeSH-major] Leptin / blood. Peptide Hormones / blood. Spinal Cord Injuries / blood

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Phys Med Rehabil. 2007 May;88(5):688
  • (PMID = 16213239.001).
  • [ISSN] 0003-9993
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Leptin; 0 / Peptide Hormones
  •  go-up   go-down


26. Richmond J, Bryant R, Trotman W, Beatty B, Lunde J: FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides. Cancer; 2006 Jun 25;108(3):198-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FISH detection of t(14;18) in follicular lymphoma on Papanicolaou-stained archival cytology slides.
  • BACKGROUND: The t(14;18)(q32;q21) translocation is present in about 85% of follicular lymphomas (FL) and can be identified using fluorescence in situ hybridization (FISH).
  • The authors proposed FISH for FL using Papanicolaou-stained archival cytology material as a practical ancillary technique for diagnosing FL.
  • METHODS: Cases included 35 FL, 6 small lymphocytic lymphomas/chronic lymphocytic leukemias (SLL/CLL), 4 mantle cell lymphomas (MCL), 4 marginal zone lymphomas (MZL), 1 lymphoplasmacytic lymphoma (LPL), and 10 reactive lymphoid tissues (RLT).
  • This series shows a sensitivity of 81% and specificity of 100% for detecting the t(14;18) translocation as a diagnostic tool in FL.
  • [MeSH-major] Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 18 / genetics. Lymphoma, Follicular / pathology. Translocation, Genetic
  • [MeSH-minor] Biopsy, Fine-Needle. Humans. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoid Tissue / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Staining and Labeling

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671111.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Alexander C, Cochran CJ, Gallicchio L, Miller SR, Flaws JA, Zacur H: Serum leptin levels, hormone levels, and hot flashes in midlife women. Fertil Steril; 2010 Aug;94(3):1037-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels, hormone levels, and hot flashes in midlife women.
  • OBJECTIVE: To examine the associations between serum leptin levels, sex steroid hormone levels, and hot flashes in normal weight and obese midlife women.
  • MAIN OUTCOME MEASURE(S): Serum leptin and sex steroid hormone levels.
  • RESULT(S): Correlation and regression models were performed to examine associations between leptin levels, hormone levels, and hot flashes.
  • Leptin levels were associated with BMI, with "ever experiencing hot flashes" (questionnaire), with hot flashes within the last 30 days, and with duration of hot flashes (>1 year, P=.03).
  • Leptin was positively correlated with testosterone, free testosterone index, and free estrogen index and inversely associated with levels of sex hormone-binding globulin.
  • In women with a body mass index>or=30 kg/m2, leptin levels no longer correlated with testosterone levels.
  • CONCLUSION(S): Serum leptin levels are associated with the occurrence and duration of hot flashes in midlife women; however, no correlation was found between leptin and serum estradiol.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2354-8 [7629229.001]
  • [Cites] Am J Obstet Gynecol. 1993 Mar;168(3 Pt 1):772-80 [8456878.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Maturitas. 1996 Apr;23(3):301-5 [8794424.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):318-21 [8989281.001]
  • [Cites] Endocrinology. 1997 Feb;138(2):847-50 [9003026.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Aug;104(8):923-33 [9255084.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):551-8 [9449624.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]
  • [Cites] Clin Exp Obstet Gynecol. 1997;24(3):163-6 [9478308.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2541-6 [9482922.001]
  • [Cites] Menopause. 1998 Spring;5(1):43-51 [9689194.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):428-34 [10022396.001]
  • [Cites] Ginekol Pol. 1999 Jan;70(1):1-7 [10349800.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7047-52 [10359836.001]
  • [Cites] Endocrine. 1999 Feb;10(1):19-23 [10403567.001]
  • [Cites] Semin Reprod Med. 2005 May;23(2):117-25 [15852197.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jul;289(1):E166-71 [15741239.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):347-51 [16098853.001]
  • [Cites] Am J Obstet Gynecol. 2005 Oct;193(4):1353-60 [16202725.001]
  • [Cites] Alcohol Alcohol. 2005 Nov-Dec;40(6):563-8 [16087658.001]
  • [Cites] Maturitas. 2006 Jan 20;53(2):217-25 [15913927.001]
  • [Cites] Maturitas. 2006 Jan 20;53(2):133-43 [16368467.001]
  • [Cites] Obstet Gynecol. 1994 Jul;84(1):29-34 [8008318.001]
  • [Cites] Maturitas. 2006 Jun 20;54(3):260-9 [16423474.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jul;65(1):125-31 [16817831.001]
  • [Cites] Climacteric. 2007 Feb;10(1):27-37 [17364602.001]
  • [Cites] Fertil Steril. 2007 Jun;87(6):1483-6 [17276432.001]
  • [Cites] Obesity (Silver Spring). 2007 Sep;15(9):2217-24 [17890489.001]
  • [Cites] Am J Epidemiol. 2008 Jan 1;167(1):78-85 [17881385.001]
  • [Cites] Maturitas. 2008 Feb 20;59(2):149-57 [18280066.001]
  • [Cites] Fertil Steril. 2008 Oct;90(4):1161-8 [18304548.001]
  • [Cites] Int J Biometeorol. 1999 Nov;43(3):99-109 [10639901.001]
  • [Cites] J Womens Health Gend Based Med. 2001 Jan-Feb;10(1):67-76 [11224946.001]
  • [Cites] Am J Hum Biol. 2001 Jul-Aug;13(4):453-64 [11400216.001]
  • [Cites] Obstet Gynecol. 2001 Sep;98(3):391-7 [11530118.001]
  • [Cites] Maturitas. 2002 Jan 30;41(1):69-77 [11809345.001]
  • [Cites] J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1417-29 [11837495.001]
  • [Cites] Atherosclerosis. 2002 Apr;161(2):455-62 [11888531.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7 [12364429.001]
  • [Cites] Obstet Gynecol. 2003 Feb;101(2):264-72 [12576249.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1189-99 [15191936.001]
  • [Cites] Endocrinology. 2004 Jul;145(7):3115-21 [15059958.001]
  • [Cites] J Gen Intern Med. 2004 Jul;19(7):740-6 [15209587.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Mar;22(3):293-312 [3884189.001]
  • [Cites] Ann Clin Biochem. 1985 Sep;22 ( Pt 5):489-97 [4062218.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Apr;64(4):723-9 [3818901.001]
  • [Cites] Int J Obes. 1989;13(1):1-9 [2703288.001]
  • [Cites] Metabolism. 1991 Jan;40(1):101-4 [1984562.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • (PMID = 19476935.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG018400-02; United States / NIA NIH HHS / AG / AG18400; United States / NIA NIH HHS / AG / R01 AG018400-03; United States / NIA NIH HHS / AG / R01 AG018400-05A2; United States / NIA NIH HHS / AG / R01 AG018400-01A1; United States / NIA NIH HHS / AG / R01 AG018400-06; United States / NIA NIH HHS / AG / R01 AG018400; United States / NIA NIH HHS / AG / R01 AG018400-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Leptin
  • [Other-IDs] NLM/ NIHMS109122; NLM/ PMC3939020
  •  go-up   go-down


28. Barth TF, Barth CA, Kestler HA, Michl P, Weniger MA, Buchholz M, Möller P, Gress T: Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma. J Pathol; 2007 Feb;211(3):305-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.
  • The pathogenetic relationship of marginal zone B-cell lymphoma (MALT lymphoma) of the gastrointestinal (GI) tract and eventually co-existing aggressive B-cell lymphoma and primary aggressive B-cell lymphoma remains to be elucidated.
  • The RNA of laser-microdissected cells was isolated and amplified from small and/or large cell compartments of eight MALT lymphomas (small cell lymphoma, SCL), 14 GI diffuse large B-cell lymphomas (large cell lymphoma, LCL), and ten GI B-cell lymphomas with composite small and large cell compartments (ComL) and expression analyses were performed using cDNA arrays.
  • Hierarchical cluster analysis clearly separated SCL and LCL and the small and large cell compartments of ComL.
  • Likewise, cluster analysis with all samples of SCL, LCL, and ComL yielded two main 'small cell' and 'large cell' branches.
  • Furthermore, 60 genes were differentially expressed between SCL and LCL, and 82 genes between the small and large cell components of ComL; 26 genes were discriminators in both settings.
  • Use of the profiles of ComL as training sets for class prediction resulted in 95% accuracy for the classification of SCL and LCL.
  • Collectively, the data strongly suggest that both secondary and primary aggressive B-cell lymphomas of the GI tract are blastic marginal zone lymphomas.
  • [MeSH-major] Gastrointestinal Neoplasms / genetics. Gene Expression Profiling. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Oligonucleotide Array Sequence Analysis. Transcription, Genetic
  • [MeSH-minor] Genetic Markers. Humans. Immunohistochemistry / methods. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17152084.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


29. Kramer CK, von Mühlen D, Barrett-Connor E: Does leptin predict incident hypertension in older adults? Clin Endocrinol (Oxf); 2010 Aug;73(2):201-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does leptin predict incident hypertension in older adults?
  • OBJECTIVE: Leptin is associated with blood pressure (BP) in experimental and cross-sectional studies, but only one previous prospective study of middle-aged men has reported the association between leptin and incident hypertension.
  • We examined the association of leptin levels with incident hypertension in a population-based study of older men and women.
  • POPULATION: Participants were 602 community-dwelling older adults with normal baseline BP levels who attended a research clinic visit between 1984 and 1987 and again 4.4 years later (mean age was 66.2 +/- 11.4; 60.6% were men; mean body mass index (BMI) 24.9 +/- 3.4 kg/m(2)).
  • Leptin was measured by radioimmunoassay.
  • Baseline serum leptin levels were higher in participants who developed hypertension compared to persistent normotensives [median (25th-75th range)] [8.8(5-16) vs 7(4-11) ng/ml, P = 0.002].
  • In logistic regression models, leptin (log-transformed) predicted incident hypertension before and after adjustments for baseline age, BMI, systolic BP, total cholesterol, medications, and previous cardiovascular disease (OR 1.75 95% CI 1.17-2.61, P = 0.006).
  • CONCLUSION: Higher leptin levels were independently associated with increased odds of incident hypertension in older adults.

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2009 Mar;53(3):473-9 [19204185.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):3922-6 [18682500.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1137-44 [19174500.001]
  • [Cites] Am J Hypertens. 2009 May;22(5):577-80 [19229195.001]
  • [Cites] Hypertension. 2009 Jun;53(6):965-72 [19398660.001]
  • [Cites] J Vasc Res. 2009;46(6):609-17 [19571581.001]
  • [Cites] Diabetes Care. 2000 Jan;23(1):57-63 [10857969.001]
  • [Cites] Hypertens Res. 2000 Jul;23(4):303-10 [10912765.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Jan;25(1):121-5 [11244467.001]
  • [Cites] Metabolism. 2001 Mar;50(3):325-9 [11230786.001]
  • [Cites] Clin Exp Hypertens. 2001 May;23(4):357-68 [11349826.001]
  • [Cites] J Neuroendocrinol. 2001 Oct;13(10):913-21 [11679060.001]
  • [Cites] J Clin Invest. 2002 Oct;110(8):1093-103 [12393845.001]
  • [Cites] Obes Res. 2003 Jan;11(1):160-6 [12529499.001]
  • [Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4823-31 [14557461.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Prev Med. 1976 Jun;5(2):207-15 [935073.001]
  • [Cites] Am J Epidemiol. 1980 Jun;111(6):705-12 [7386445.001]
  • [Cites] Hypertension. 1997 Sep;30(3 Pt 2):619-23 [9322991.001]
  • [Cites] Hypertension. 1998 Jan;31(1 Pt 2):409-14 [9453337.001]
  • [Cites] Eur J Pharmacol. 2005 Aug 22;518(2-3):175-81 [16054621.001]
  • [Cites] J Hypertens. 2006 May;24(5):789-801 [16612235.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):532-41 [17118991.001]
  • [Cites] Am J Clin Nutr. 2009 Mar;89(3):991S-997S [19176740.001]
  • (PMID = 20148909.001).
  • [ISSN] 1365-2265
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG028507-03; United States / NIDDK NIH HHS / DK / R01 DK031801-15; United States / NIA NIH HHS / AG / R01 AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-13S1; United States / NIA NIH HHS / AG / AG007181-13S1; United States / NIA NIH HHS / AG / R01 AG028507-02; United States / NIA NIH HHS / AG / R01 AG007181; United States / NIA NIH HHS / AG / AG07181; United States / NIDDK NIH HHS / DK / R01 DK031801; United States / NIA NIH HHS / AG / AG007181-13; United States / NIA NIH HHS / AG / R01 AG007181-13; United States / NIDDK NIH HHS / DK / R01 DK031801-16; United States / NIDDK NIH HHS / DK / DK31801; United States / NIA NIH HHS / AG / R01 AG028507-03; United States / NIA NIH HHS / AG / AG028507-02; United States / NIA NIH HHS / AG / AG007181-12; United States / NIA NIH HHS / AG / R01 AG007181-14; United States / NIA NIH HHS / AG / R37 AG007181; United States / NIA NIH HHS / AG / R01 AG028507; United States / NIA NIH HHS / AG / AG028507
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Leptin
  • [Other-IDs] NLM/ NIHMS175266; NLM/ PMC2891171
  •  go-up   go-down


30. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, Gonzalez-Juanatey C, Miranda-Filloy JA, Vazquez-Rodriguez TR, de Matias JM, Martin J, Dessein PH, Llorca J: Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. Clin Exp Rheumatol; 2009 Mar-Apr;27(2):222-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis.
  • OBJECTIVE: The adipocytokine leptin regulates weight centrally and participates in the regulation of the immune and inflammatory responses.
  • In the present study we investigated whether inflammation, obesity or both of these characteristics are potential determinants of circulating leptin concentrations in a group of RA patients on periodical treatment with the TNF-alpha-blocker-infliximab due to severe disease.
  • We also assessed whether the infusion of infliximab may alter circulating leptin concentrations in patients with severe RA.
  • Serum leptin levels were determined immediately prior to and after infliximab infusion.
  • RESULTS: There was a positive correlation between body mass index of RA patients and baseline serum level of leptin (rho=0.665, p<0.001).
  • Apart from a significant correlation with VCAM-1 (rho=0.349, p=0.04), no significant correlations between baseline leptin levels and the age at the time of the study or at the onset of the disease, disease duration, ESR and CRP levels, DAS28, lipids, insulin sensitivity, adhesion molecules, resistin, adiponectin, ghrelin or the cumulative prednisone dose at the time of the study were found.
  • Leptin levels did not change upon infliximab infusion (p=0.48).
  • CONCLUSION: In RA patients on TNF-alpha blocker treatment, circulating leptin levels are unrelated to disease activity but constitute a manifestation of adiposity.
  • The beneficial effect of anti-TNF-alpha therapy on cardiovascular mortality in RA does not seem to be mediated by reduction in serum levels of leptin.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Arthritis, Rheumatoid / blood. Arthritis, Rheumatoid / drug therapy. Leptin / blood. Obesity / blood. Tumor Necrosis Factor-alpha / antagonists & inhibitors


31. Bourdon C, Hojna S, Jordan M, Bérubé J, Kren V, Pravenec M, Liu P, Arab S, Pausová Z: Genetic locus on rat chromosome 20 regulates diet-induced adipocyte hypertrophy: a microarray gene expression study. Physiol Genomics; 2009 Jun 10;38(1):63-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In response to HFD, body weight, fat pad weights, adipocyte size, and serum leptin levels increased significantly more in SHR.1N than SHR.
  • Microarray gene expression profiles [Affymetrix, 15,923 genes and expressed sequence tags (ESTs)] showed that multiple genes of molecular pathways involved in lipogenesis were downregulated to a similar level in both strains, whereas genes involved in fatty acid oxidation and energy dissipation were upregulated less in SHR.1N than SHR.

  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2000 Jul;36(1):14-9 [10904006.001]
  • [Cites] Nature. 2008 Aug 21;454(7207):961-7 [18719582.001]
  • [Cites] Cell. 2001 Sep 7;106(5):563-73 [11551504.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1876-83 [12031976.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11888-96 [12529376.001]
  • [Cites] Cell. 2003 Apr 18;113(2):159-70 [12705865.001]
  • [Cites] Hypertension. 2003 May;41(5):1047-55 [12654711.001]
  • [Cites] J Clin Invest. 2003 Dec;112(12):1796-808 [14679176.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):277-359 [14715917.001]
  • [Cites] Science. 2004 May 28;304(5675):1301-5 [15166374.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Jul;287(1):R112-9 [15001430.001]
  • [Cites] Nature. 2004 Sep 9;431(7005):200-5 [15306821.001]
  • [Cites] Cell. 1982 May;29(1):53-60 [7105184.001]
  • [Cites] Biochem J. 1988 Feb 1;249(3):765-9 [3355496.001]
  • [Cites] Mol Endocrinol. 1988 May;2(5):395-403 [2901666.001]
  • [Cites] J Hypertens. 1989 Mar;7(3):217-21 [2708818.001]
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] J Clin Invest. 1995 Jul;96(1):158-62 [7615786.001]
  • [Cites] J Clin Invest. 1995 Dec;96(6):2914-23 [8675663.001]
  • [Cites] Diabetes. 1997 Sep;46(9):1468-72 [9287048.001]
  • [Cites] Eur J Clin Invest. 1998 Jan;28(1):59-66 [9502188.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):412-20 [9664083.001]
  • [Cites] J Clin Invest. 2004 Dec;114(12):1752-61 [15599400.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):15493-6 [15746100.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2005 Jul;73(1):31-4 [15936931.001]
  • [Cites] Biol Cell. 2005 Jul;97(7):479-86 [15966863.001]
  • [Cites] FASEB J. 2005 Sep;19(11):1567-9 [16009704.001]
  • [Cites] Am J Hypertens. 2005 Oct;18(10):1271-5 [16202847.001]
  • [Cites] Annu Rev Cell Dev Biol. 2005;21:247-69 [16212495.001]
  • [Cites] Obes Res. 2005 Dec;13(12):2122-31 [16421346.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2006 Mar;15(2):173-8 [16481885.001]
  • [Cites] Cell Metab. 2006 Mar;3(3):223-9 [16517409.001]
  • [Cites] Exp Hematol. 2006 Aug;34(8):1106-14 [16863918.001]
  • [Cites] Biochem J. 2006 Sep 1;398(2):153-68 [16898874.001]
  • [Cites] Nature. 2006 Dec 14;444(7121):847-53 [17167472.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4401-6 [17360536.001]
  • [Cites] Int J Obes (Lond). 2007 Jun;31(6):1004-13 [17130847.001]
  • [Cites] J Lipid Res. 2007 Dec;48(12):2751-61 [17872589.001]
  • [Cites] FEBS Lett. 2008 Jan 9;582(1):117-31 [18037376.001]
  • [Cites] Mol Endocrinol. 2008 May;22(5):1023-31 [18202144.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Aug;295(2):E356-67 [18492779.001]
  • [Cites] Curr Hypertens Rep. 1999 Feb-Mar;1(1):42-50 [10981041.001]
  • (PMID = 19383622.001).
  • [ISSN] 1531-2267
  • [Journal-full-title] Physiological genomics
  • [ISO-abbreviation] Physiol. Genomics
  • [Language] ENG
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Leptin
  • [Other-IDs] NLM/ PMC2696153
  •  go-up   go-down


32. Horoz M, Aslan M, Koylu AO, Bolukbas C, Bolukbas FF, Selek S, Erel O: The relationship between leptin level and oxidative status parameters in hemodialysis patients. Artif Organs; 2009 Jan;33(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between leptin level and oxidative status parameters in hemodialysis patients.
  • Both serum leptin level and oxidative stress are increased in hemodialysis (HD) patients.
  • In the present study, we aimed to investigate whether there is association between oxidative status and leptin level in HD patients.
  • Serum leptin level, total peroxide (TP) level, total antioxidant capacity (TAC), and oxidative stress index (OSI) were determined.
  • Serum leptin level, TP level, and OSI were significantly higher in HD patients than controls (all P < 0.001) while TAC was lower (P < 0.001).
  • In HD patients, serum leptin level was significantly correlated with TP level and OSI (r = 0.372, P < 0.001 and r = 0.409, P < 0.001, respectively).
  • The correlation of serum leptin level with TP level and OSI remained statistically significant after adjusting for age, gender, and body-fat percentage (r = 0.446, P < 0.001 and r = 0.463, P < 0.001, respectively).
  • Hyperleptinemia seems to be associated with increased oxidative stress in HD patients, and this association may provide better understanding about the disorders related to either elevated serum leptin levels and/or increased oxidative stress in HD patients.
  • [MeSH-major] Leptin / blood. Oxidative Stress. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178446.001).
  • [ISSN] 1525-1594
  • [Journal-full-title] Artificial organs
  • [ISO-abbreviation] Artif Organs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Leptin; 0 / Peroxides
  •  go-up   go-down


33. Shabat S, Nyska M, Eintacht S, Lis M, Bogomolni A, Berner Y, Kestanbaum-Shainkin R: Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling. Arch Gerontol Geriatr; 2009 Mar-Apr;48(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin level in geriatric patients with hip fractures: possible correlation to biochemical parameters of bone remodeling.
  • Since leptin was suggested to be involved in bone remodeling, its possible involvement in fracture formation/prevention was evaluated, by determination of serum leptin level in geriatric population with hip fracture, and evaluation the relationships with biochemical parameters of bone remodeling.
  • Serum leptin level of this total population distributed between 1 and 134ng/ml.
  • 40% of patients were in the normal range of our laboratory (10-40ng/ml), 40% had decreased leptin level (<10ng/ml) and 20% had higher leptin level (>40ng/ml).
  • No correlation was detected between serum leptin level and vitamin D-25(OH)D3, which was under normal range in 60% of the patients.
  • Leptin also did not correlate to ICTP level, which was high in 80% of the patients, suggesting an extensive bone resorption in this population.
  • Evaluation of leptin level in female versus male suggests that leptin level is higher in females than males also in this age (28.4ng/ml vs. 14.4ng/ml, p<0.001).
  • The higher leptin levels in women was accompanied by higher serum levels of glucose, albumin, Ca, cholesterol, Na and FT4.
  • Comparison of 50 patients with the lowest leptin levels (mean of 3.4ng/ml) to 50 patients with highest leptin levels (mean of 34ng/ml), did not indicate differences in both 25(OH)D3 and ICTP between these two populations in spite of the highly significant difference in leptin levels.
  • The high range of serum leptin concentration in these geriatric patients with hip fracture of both sexes, and the absence of any correlation between leptin and the tested parameters of bone resorption and Ca metabolism, teleopeptide type I collagen (ICTP) and 25(OH)D3, does not support a direct massive involvement of serum leptin in hip fracture of the very old population.
  • [MeSH-major] Bone Remodeling / physiology. Hip Fractures / blood. Leptin / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers / blood. Calcifediol / blood. Case-Control Studies. Cohort Studies. Collagen Type I. Dihydroxycholecalciferols / blood. Female. Humans. Male. Peptide Fragments / blood. Peptides. Procollagen / blood. Sex Distribution

  • MedlinePlus Health Information. consumer health - Hip Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18359113.001).
  • [ISSN] 1872-6976
  • [Journal-full-title] Archives of gerontology and geriatrics
  • [ISO-abbreviation] Arch Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Collagen Type I; 0 / Dihydroxycholecalciferols; 0 / Leptin; 0 / Peptide Fragments; 0 / Peptides; 0 / Procollagen; 0 / collagen type I trimeric cross-linked peptide; P6YZ13C99Q / Calcifediol
  •  go-up   go-down


34. Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A: Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma. Leuk Lymphoma; 2006 Sep;47(9):1818-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
  • Although numerous options are available for patients with recurrent low-grade non-Hodgkin's lymphoma (NHL), responses are rarely durable.
  • We previously conducted a phase I trial of fludarabine and paclitaxel in the treatment of recurrent low-grade lymphoma.
  • Twenty-two (78%) patients had grade 1 or 2 follicular lymphoma, and six patients (21%) had small lymphocytic lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Male. Middle Aged. Paclitaxel / administration & dosage. Survival Rate. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064994.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


35. Biggar RJ, Christiansen M, Rostgaard K, Smedby KE, Adami HO, Glimelius B, Hjalgrim H, Melbye M: Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma. Int J Cancer; 2009 Jun 1;124(11):2616-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma.
  • Allergy/atopy has been suggested to protect against non-Hodgkin lymphoma (NHL) and specific IgE levels are decreased in patients with NHL.
  • We speculated that all immunoglobulin subclass levels might be downregulated in NHL and examined levels of IgM, IgD, IgA, IgE, IgG and IgG(4) in 200 NHL patients and 200 age- and sex-matched controls.
  • Patients with B-cell NHL of many types had consistently lower median immunoglobulin subclass levels than controls.
  • In every subclass except IgD, about 10-15% of B-cell NHL patients had absolute levels below the 2.5 percentile of controls.
  • Subclass levels correlated with each other and many patients had more than one significantly low level.
  • Levels were lowest for IgG(4) and IgE.
  • Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma had especially low total IgE levels.
  • In other B-cell NHL types, total IgE levels were decreased to a similar extent as other immunoglobulin subclasses.
  • In conclusion, low IgE levels are only part of a more generalized loss of immunoglobulins of all subtypes in a wide variety of B-cell NHL types.
  • Low immunoglobulin levels appear to be a consequence of B-cell NHL presence, and we speculate about molecular mechanisms that could reduce all immunoglobulin subclasses in B-cell NHL.
  • [MeSH-major] Immunoglobulins / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD80 / blood. Female. Humans. Immunoglobulin E / blood. Immunoglobulin G / blood. Immunoglobulin M / blood. Lymphoma, Non-Hodgkin / immunology. Male. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235925.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulins; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


36. Kuriakose P: Targeted therapy for hematologic malignancies. Cancer Control; 2005 Apr;12(2):82-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the use of small molecules against specific cell surface receptors, enzymes, and proteins has become an important strategy in the treatment of such disorders.
  • Nevertheless, additional studies are needed to determine where and when such management fits into a therapeutic regimen for any given disorder, whether upfront or as salvage therapy, alone or in combination with chemotherapy (concurrent or sequential).
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / immunology. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Radioimmunotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15855891.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Immunologic Factors
  • [Number-of-references] 129
  •  go-up   go-down


37. Mao J, Yang T, Gu Z, Heird WC, Finegold MJ, Lee B, Wakil SJ: aP2-Cre-mediated inactivation of acetyl-CoA carboxylase 1 causes growth retardation and reduced lipid accumulation in adipose tissues. Proc Natl Acad Sci U S A; 2009 Oct 13;106(41):17576-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FACC1KO mice showed prenatal growth retardation; after weaning, however, their weight gain was comparable to that of wild-type (WT) mice on a normal diet.
  • In addition, there was about a 30% decrease in serum insulin-like growth factor I (IGF1), and while the serum leptin level was decreased by about 50%, it did not counteract the osteopenic effects of IGF1 on the bone.
  • Fatty acid analyses of mutant bone lipids revealed relatively higher levels of C18:2n-6 and C18:3n-3 and lower levels of their elongation C20 homologs than that of WT cohorts, leading to lower levels of C20 homologs and bone development.

  • MedlinePlus Health Information. consumer health - Growth Disorders.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1964 Feb;239:375-80 [14169133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]
  • [Cites] Expert Opin Ther Targets. 2005 Apr;9(2):267-81 [15934915.001]
  • [Cites] Cell Metab. 2005 Feb;1(2):107-19 [16054052.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12011-6 [16103361.001]
  • [Cites] Cell Mol Life Sci. 2005 Aug;62(16):1784-803 [15968460.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1063-76 [16428458.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 30;103(22):8552-7 [16717184.001]
  • [Cites] J Bone Miner Res. 2006 Sep;21(9):1350-8 [16939393.001]
  • [Cites] Transgenic Res. 2006 Oct;15(5):647-53 [16952017.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4753-61 [16857753.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Mar 15;17(6):1803-7 [17234407.001]
  • [Cites] Gastroenterology. 2007 May;132(6):2103-15 [17498506.001]
  • [Cites] Cell. 2007 Aug 10;130(3):456-69 [17693256.001]
  • [Cites] Nat Med. 2008 Mar;14(3):299-305 [18297084.001]
  • [Cites] Cell. 2000 Jan 21;100(2):197-207 [10660043.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • [Cites] Endocr Rev. 2000 Aug;21(4):393-411 [10950158.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4436-41 [11108252.001]
  • [Cites] Dev Biol. 2001 Jan 1;229(1):141-62 [11133160.001]
  • [Cites] Prog Lipid Res. 2001 Jan-Mar;40(1-2):125-48 [11137570.001]
  • [Cites] Trends Endocrinol Metab. 2000 Oct;11(8):327-32 [10996528.001]
  • [Cites] Science. 2001 Mar 30;291(5513):2613-6 [11283375.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):127-35 [11485560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):138-43 [11756679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7515-20 [12810950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15712-7 [14660788.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3258-63 [14978271.001]
  • [Cites] Methods Enzymol. 1975;35:59-65 [235706.001]
  • [Cites] J Biol Chem. 1983 Sep 25;258(18):11074-81 [6136512.001]
  • [Cites] Annu Rev Biochem. 1983;52:537-79 [6137188.001]
  • [Cites] J Biol Chem. 1985 May 25;260(10):6318-23 [2860106.001]
  • [Cites] J Biol Chem. 1988 May 5;263(13):6447-53 [2896193.001]
  • [Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]
  • [Cites] Genes Dev. 1993 Dec;7(12B):2609-17 [8276243.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Gene. 1995 Mar 10;154(2):271-5 [7890176.001]
  • [Cites] Brain Res Dev Brain Res. 1997 Feb 20;98(2):197-203 [9051261.001]
  • [Cites] Annu Rev Nutr. 1997;17:77-99 [9240920.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):1025-36 [10215629.001]
  • [Cites] J Nutr Biochem. 2004 Nov;15(11):651-6 [15590268.001]
  • (PMID = 19805143.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM063115; United States / NIGMS NIH HHS / GM / GM-63115
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.- / aminoglycoside N1-acetyltransferase; EC 6.4.1.2 / Acetyl-CoA Carboxylase
  • [Other-IDs] NLM/ PMC2762677
  •  go-up   go-down


38. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • The remaining 36 patients had to be excluded because numbers were too small for statistical analysis or unreliable staging.
  • In contrast gender, staging by Rye or Rai classification, retroviral infection and prior treatment with radiotherapy were without effect.
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for diagnosis, staging and treatment.
  • Under these circumstances the well recognized centre effect applies when results approximate those from first world reference centres.
  • [MeSH-major] Lymphoma

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


39. Gogas H, Trakatelli M, Dessypris N, Terzidis A, Katsambas A, Chrousos GP, Petridou ET: Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study. Ann Oncol; 2008 Feb;19(2):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.
  • BACKGROUND: Solar radiation has been identified as a principal factor for the causation of melanoma, whereas changing lifestyle patterns associated with obesity and diabetes might also contribute to the increasing incidence of the malignancy.
  • No study has investigated the role of leptin, a hormone whose levels increase in obesity and which has also been related to cancer.
  • Anthropometrical measures were also recorded and blood samples were obtained for determination of serum leptin levels.
  • RESULTS: An excess melanoma risk was observed for sun sensitive individuals and those with high circulating levels of leptin (OR: 1.56, 95% confidence interval 1.07-2.28, P = 0.02), after controlling for obesity indices, diabetes mellitus and education.
  • CONCLUSIONS: Melanoma risk was found to be positively associated with serum leptin levels and inversely with healthy lifestyle factors.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925285.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


40. Rao SN, Gurumurthy GP, Gururajan P, Arumugam SB, Saibabu, Kirthivasan V, Cherian KM: Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents. Indian J Pediatr; 2010 May;77(5):555-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biochemical parameters in relation to serum leptin levels in South Indian children and adolescents.
  • OBJECTIVE: To investigate the relationship between serum leptin and lipid profile in South Indian School children and adolescents, and to evaluate the role of serum leptin in obese, overweight and congenital heart diseased children and adolescents; in South Indian population and its correlation with anthropometric and biochemical parameters.
  • Anthropometric variables, lipid profile, fasting serum glucose were analyzed by autoanalyser and serum leptin by ELISA.
  • RESULTS: Serum leptin levels were significantly elevated in obese and overweight children than in control children (36.88+/-18.60ng/mL, 20.64+/-11.18ng/mL vs 7.97+/-2.79ng/mL; p value <0.001), and decreased in congenital heart diseased children than in control children (6.20+/-4.23 ng/mL vs 7.97+/-2.79ng/mL; p value <0.005).
  • CONCLUSIONS: This study provides a good relationship between serum leptin levels and anthropometric and biochemical parameters, such as total cholesterol, triglycerides and LDL-cholesterol.
  • We observed negative correlation between serum leptin and fasting glucose levels and HDL-cholesterol levels were found to be non-significant among the groups.
  • Further studies with large sample size are needed to ascertain the relationship between serum leptin and lipid profile in different groups of children and adolescents.
  • [MeSH-major] Heart Defects, Congenital / blood. Leptin / blood. Lipids / blood. Obesity / blood. Overweight / blood

  • MedlinePlus Health Information. consumer health - Congenital Heart Defects.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):808-13 [9259579.001]
  • [Cites] J Clin Invest. 2000 May;105(9):1243-52 [10791999.001]
  • [Cites] Obes Res. 2003 Apr;11(4):532-40 [12690082.001]
  • [Cites] Eur J Clin Nutr. 2007 Jun;61(6):719-26 [17164827.001]
  • [Cites] Ann Intern Med. 1997 Jan 1;126(1):26-31 [8992920.001]
  • [Cites] Int J Cardiol. 2003 Nov;92(1):93-7 [14602223.001]
  • [Cites] Eur J Epidemiol. 2001;17(10):911-6 [12188009.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Nov;81(11):3909-13 [8923837.001]
  • [Cites] J Intern Med. 1999 Oct;246(4):409-18 [10583712.001]
  • [Cites] Obes Res. 2005 Aug;13(8):1476-84 [16129731.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2148-52 [9215286.001]
  • [Cites] Indian Pediatr. 2007 Apr;44(4):257-62 [17468520.001]
  • [Cites] Pediatrics. 2005 Apr;115(4):e500-3 [15741351.001]
  • [Cites] Indian J Pediatr. 2006 Jul;73(7):593-6 [16877853.001]
  • [Cites] Pediatrics. 1996 Aug;98(2 Pt 1):201-3 [8692618.001]
  • (PMID = 20401706.001).
  • [ISSN] 0973-7693
  • [Journal-full-title] Indian journal of pediatrics
  • [ISO-abbreviation] Indian J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 0 / Lipids
  •  go-up   go-down


41. Dedeoğlu EN, Erenus M, Yörük P: Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertil Steril; 2009 Feb;91(2):425-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women.
  • OBJECTIVE: To compare the changes in body composition and in leptin levels in postmenopausal women receiving hormone therapy (HT) or tibolone.
  • MAIN OUTCOME MEASURE(S): Anthropometric indices, leptin levels, tissue fat percentage, total fat, and lean mass measurements were performed at baseline and after 6 months.
  • RESULT(S): The serum leptin levels were in strong correlation with the total fat percentage and total fat mass at baseline.
  • Untreated women had weight gain and a gradual decrease in leptin levels.
  • Women receiving HT had significantly increased leptin levels.
  • Women in the tibolone group, however, had a significant decrease in leptin levels accompanied by decreased total fat mass, fat percentage, and increased total lean mass.
  • The changes in leptin levels were more pronounced in lean women.
  • CONCLUSION(S): Postmenopausal women tend to gain weight accompanied with a reduction in leptin concentrations.
  • Hormone therapy administration increases leptin levels while maintaining body weight and body fat distribution, whereas tibolone use decreases leptin levels, total fat percentage, and total fat mass.
  • [MeSH-major] Adiposity / drug effects. Estrogen Replacement Therapy. Estrogens, Conjugated (USP) / therapeutic use. Leptin / blood. Medroxyprogesterone Acetate / therapeutic use. Norpregnenes / therapeutic use. Postmenopause. Weight Gain / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18249383.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Conjugated (USP); 0 / Leptin; 0 / Norpregnenes; C2QI4IOI2G / Medroxyprogesterone Acetate; FF9X0205V2 / tibolone
  •  go-up   go-down


42. Li L, Gao Y, Zhang LL, He DL: Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther; 2008 Nov;7(11):1787-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells.
  • Serum leptin levels are often elevated in obese people.
  • Leptin has been reported to act as a mitogenic agent and promote renal cancer cell proliferation, whereas the detailed mechanisms still remain to be elucidated.
  • The purpose of this study is to investigate the proliferation and mobility effects in leptin-treated Caki-2 renal cell carcinoma and analyze the alterations of leptin-inducible STAT3 pathways and mitogenic signaling ERK pathways.
  • Our results indicate the constitutive expression of leptin receptor could not be upregulated upon the stimulation of leptin in Caki-2 cells.
  • Leptin increases the proliferation and mobility capabilities of Caki-2 cells via upregulating the expression of both phosphor-ERK and phosphor-STAT3 and these two pathways could be partially abolished by inhibition of the activation of JAK-STAT3 and completely abrogated by inhibition of ERK1/2 pathways.
  • Our results also suggest that mitogenic actions of leptin are not the consequence of altered its receptor expression; whereas the cellular proliferation appears to be working through the cross-talking of JAK-STAT3 and ERK1/2 pathways in renal cell carcinoma caki-2 cells.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation. Janus Kinase 1 / metabolism. Leptin / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Flow Cytometry. Humans. Kidney Neoplasms / metabolism. MAP Kinase Signaling System. Obesity / metabolism. Protein Kinase C / metabolism. Signal Transduction

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18787400.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / STAT3 Transcription Factor; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


43. Xu LP, Huang XJ, Liu DH, Chen YH, Shi HX, Chen DB: [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation]. Zhonghua Nei Ke Za Zhi; 2007 Dec;46(12):996-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
  • OBJECTIVE: To study the risk factors and clinical characteristics of post transplantation lymphoproliferative disorders (PTLD) after hematopoietic stem cell transplantation (HSCT).
  • PTLD was diagnosed on the basis of finding diffuse hyperplasia characterized by invasion of other organ structure with disorganization of the nodal structure in lymph nodes.
  • If pathological investigation was not possible, PTLD was diagnosed by the presence of fever, lymph node enlargement and/or EBV viral load, which could not be explained by other causes.
  • The morphology of biopsy appeared as small B-lymphocytic lymphoma; there was no response to chemotherapy and the patients died.
  • One patient recovered by reducing immunosuppressive drug therapy combined with MP and one patient recovered by reducing immunosuppressive/antivirus therapy and donor lymphocyte infusion.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478915.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


44. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S: Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med; 2007 Jan 18;356(3):237-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor.
  • BACKGROUND: A single family has been described in which obesity results from a mutation in the leptin-receptor gene (LEPR), but the prevalence of such mutations in severe, early-onset obesity has not been systematically examined.
  • Serum leptin levels were within the range predicted by the elevated fat mass in these subjects.
  • Their clinical features were less severe than those of subjects with congenital leptin deficiency.
  • Circulating levels of leptin were not disproportionately elevated, suggesting that serum leptin cannot be used as a marker for leptin-receptor deficiency.
  • Congenital leptin-receptor deficiency should be considered in the differential diagnosis in any child with hyperphagia and severe obesity in the absence of developmental delay or dysmorphism.
  • [MeSH-major] Metabolism, Inborn Errors / diagnosis. Metabolism, Inborn Errors / genetics. Obesity / genetics. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Age of Onset. Basal Metabolism. Body Composition. Child. Diagnosis, Differential. Female. Genotype. Humans. Hyperphagia / blood. Hyperphagia / complications. Hyperphagia / genetics. Hypogonadism / blood. Hypogonadism / complications. Hypogonadism / genetics. Immunologic Deficiency Syndromes / blood. Immunologic Deficiency Syndromes / complications. Immunologic Deficiency Syndromes / genetics. Leptin / blood. Lymphocyte Count. Male. Mutation. Pedigree. Phenotype. Receptors, Leptin


45. Gui W, Zhao ZQ, Zhang Z, Guo YR, Zhang QH, Su W: [Analysis of pathological type and clinical features of lymphoma cell leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2009 Oct;30(10):662-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of pathological type and clinical features of lymphoma cell leukemia].
  • OBJECTIVE: To analyze the pathological type and clinical features of patients with lymphoma cell leukemia (LML).
  • METHODS: According to the 2008 WHO classification of tumors of hematopoietic and lymphoid tissue, the pathological type and clinical features of 127 LML cases were analyzed retrospectively.
  • The incidence in frequent order of them was B-lymphoblastic lymphoma, CLL/small lymphocytic lymphoma (SLL) and T-lymphoblastic lymphoma.
  • The LML of T and B cell subtypes were 45 and 74, respectively.
  • Eighty one patients presented LML at the same time of the NHL diagnosis and 46 during the course (1 - 88 months) of disease.
  • The clinical manifestations of LBL and SLL patients differed from that of ALL and CLL patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954660.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Halldórsdóttir AM, Zehnbauer BA, Burack WR: Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular lymphoma specimens: superior performance of the IGK assays compared to IGH for suboptimal specimens. Leuk Lymphoma; 2007 Jul;48(7):1338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of BIOMED-2 clonality assays to formalin-fixed paraffin embedded follicular lymphoma specimens: superior performance of the IGK assays compared to IGH for suboptimal specimens.
  • The BIOMED-2 PCR-based immunoglobulin gene rearrangement assays have quickly become the most commonly used laboratory method for detection of B-cell clonality.
  • When studying paired cases of follicular lymphoma (FL) from individual patients, we used these assays to assess clonality in 40 formalin-fixed paraffin-embedded (FFPE) specimens from 19 patients diagnosed with FL.
  • The high failure rate of the IGH assays for this set of FFPE lymphomas cannot be explained by systematic problems with DNA extraction or amplification because the same IGH assays resulted in a low failure rate (3/32, 9%) for FFPE small lymphocytic lymphoma/chronic lymphocytic leukemia specimens and for fresh frozen FL specimens (1/6, 17%).
  • Furthermore, in a second validation set of 13 FFPE follicular lymphoma the failure rate was 9/13 (69%).
  • Therefore, the BIOMED-2 IGH assay did not perform well on FFPE follicular lymphoma specimens, and the IGK assay may be superior for assessing clonality when no fresh/frozen tissue is available.
  • [MeSH-major] B-Lymphocytes / pathology. Clone Cells / pathology. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics. Lymphoma, Follicular / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613763.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


47. Matheny M, Zhang Y, Shapiro A, Tümer N, Scarpace PJ: Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis. Am J Physiol Regul Integr Comp Physiol; 2009 Nov;297(5):R1254-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central overexpression of leptin antagonist reduces wheel running and underscores importance of endogenous leptin receptor activity in energy homeostasis.
  • We used recombinant adeno-associated virus (rAAV)-mediated gene delivery to overexpress a mutant of rat leptin yielding a protein that acts as a neutral leptin receptor antagonist.
  • Leptin antagonist overexpression was confirmed by examination of mRNA levels in the hypothalamus.
  • The degree of antagonist overexpression was sufficient to partially block signal transducer and activator of transcription 3 (STAT3) phosphorylation due to administration of an acute submaximal dose of leptin.
  • In contrast, when leptin was overexpressed in the hypothalamus, WR activity was increased by greater than twofold.
  • At death, adiposity and serum leptin levels were greater in the antagonist group.
  • These data indicate that submaximal central leptin receptor blockade promotes obesity and diminishes WR activity.
  • These findings underscore the critical role of unrestrained leptin receptor activity in long-term energy homeostasis and suggest that even minor disruption of leptin receptor function can promote obesity.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Apr 6;404(6778):661-71 [10766253.001]
  • [Cites] J Clin Invest. 1995 Sep;96(3):1658-63 [7657836.001]
  • [Cites] J Clin Invest. 2000 Jun;105(12):1827-32 [10862798.001]
  • [Cites] Regul Pept. 2001 Jun 15;99(2-3):69-77 [11384767.001]
  • [Cites] Neuroscience. 2001;104(4):1111-7 [11457594.001]
  • [Cites] Neuropharmacology. 2002 Mar;42(4):548-61 [11955525.001]
  • [Cites] Obes Rev. 2000 Oct;1(2):87-94 [12119990.001]
  • [Cites] Endocrinology. 2002 Aug;143(8):3026-35 [12130569.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8878-83 [9238071.001]
  • [Cites] Am J Physiol. 1997 Jul;273(1 Pt 1):E226-30 [9252501.001]
  • [Cites] Diabetes. 1997 Nov;46(11):1782-5 [9356026.001]
  • [Cites] Nat Genet. 1998 Mar;18(3):213-5 [9500540.001]
  • [Cites] Endocrinology. 1998 Sep;139(9):3681-90 [9724018.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):763-70 [9796811.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17541-4 [10364187.001]
  • [Cites] Nat Biotechnol. 2004 Dec;22(12):1583-7 [15568020.001]
  • [Cites] Diabetologia. 2005 Jun;48(6):1075-83 [15864530.001]
  • [Cites] J Virol. 2006 Feb;80(4):1874-85 [16439543.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Feb;320(2):706-12 [17082312.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R868-74 [17023670.001]
  • [Cites] Front Biosci. 2007;12:3531-44 [17485319.001]
  • [Cites] Behav Brain Res. 2008 Mar 17;188(1):100-8 [18063139.001]
  • [Cites] Diabetes. 2008 Mar;57(3):614-22 [18086903.001]
  • [Cites] Endocrinology. 2008 Jun;149(6):3009-15 [18308842.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2008 Nov;295(5):R1370-5 [18703413.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Sep;227(8):587-600 [12192100.001]
  • [Cites] Methods. 2002 Oct;28(2):158-67 [12413414.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Mar;12(3):373-8 [12605561.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Nov;285(5):R1011-20 [14557234.001]
  • [Cites] Obes Res. 2004 Jan;12(1):150-60 [14742854.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4531-6 [15070752.001]
  • [Cites] Metabolism. 1977 Apr;26(4):371-80 [846405.001]
  • [Cites] Q J Exp Physiol. 1987 Oct;72(4):549-59 [3423201.001]
  • [Cites] Science. 1995 Jul 28;269(5223):543-6 [7624777.001]
  • [Cites] Science. 1995 Jul 28;269(5223):546-9 [7624778.001]
  • [Cites] Annu Rev Physiol. 2000;62:413-37 [10845097.001]
  • (PMID = 19726711.001).
  • [ISSN] 1522-1490
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / AG-26159; United States / NIA NIH HHS / AG / P30-AG-028740,
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ion Channels; 0 / Leptin; 0 / Mitochondrial Proteins; 0 / RNA, Messenger; 0 / Receptors, Leptin; 0 / STAT3 Transcription Factor; 0 / Stat3 protein, rat; 0 / mitochondrial uncoupling protein
  • [Other-IDs] NLM/ PMC2777784
  •  go-up   go-down


48. Benetti-Pinto CL, Castro N, Grassiotto Oda R, Garmes HM: Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles. Menopause; 2010 Jan-Feb;17(1):174-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin and adiponectin blood levels in women with premature ovarian failure and age- and weight-matched women with normal menstrual cycles.
  • OBJECTIVE: The aim of this study was to evaluate leptin and adiponectin blood levels in women with premature ovarian failure (POF) and women with a normal menstrual cycle.
  • Serum leptin levels were significantly lower in G1 compared with G2 (8.8 +/- 12.2 and 12.2 +/- 9.7 ng/mL; P < 0.05).
  • Serum adiponectin levels were similar in both groups.
  • Leptin levels were positively correlated to weight (r = 0.38; P = 0.03) but were not correlated to BMI and age in women with POF (G1); in G2, they were positively correlated to BMI (r = 0.59; P = 0.0006), weight (r = 0.63; P = 0.0006), and age (r = 0.40; P = 0.02).
  • Adiponectin levels did not correlate to weight, BMI, or age in both groups.
  • CONCLUSIONS: These results suggest that gonadal function loss may decrease leptin circulating levels, independently from age and BMI.
  • [MeSH-major] Adiponectin / blood. Leptin / blood. Primary Ovarian Insufficiency / blood

  • Genetic Alliance. consumer health - premature ovarian failure.
  • MedlinePlus Health Information. consumer health - Premature Ovarian Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19609224.001).
  • [ISSN] 1530-0374
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Leptin
  •  go-up   go-down


49. Ruhlen RL, Howdeshell KL, Mao J, Taylor JA, Bronson FH, Newbold RR, Welshons WV, vom Saal FS: Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice. Environ Health Perspect; 2008 Mar;116(3):322-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low phytoestrogen levels in feed increase fetal serum estradiol resulting in the "fetal estrogenization syndrome" and obesity in CD-1 mice.
  • RESULTS: In fetuses whose mothers consumed the low-phytoestrogen PMI 5K96 feed, we found a paradoxical significant elevation in endogenous serum estradiol, which was associated postnatally with adverse reproductive outcomes referred to as the "fetal estrogenization syndrome (FES)".
  • The low-phytoestrogen-fed males and females were lighter at birth, but, between weaning and adulthood, they became obese and developed abnormally high serum leptin levels; these males, but not females, showed impaired glucose regulation.

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2056-61 [9050904.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(8):994-1006 [12826473.001]
  • [Cites] Toxicol Ind Health. 1998 Jan-Apr;14(1-2):239-60 [9460178.001]
  • [Cites] Environ Health Perspect. 1998 Jul;106(7):369-73 [9637793.001]
  • [Cites] Epidemiol Rev. 1998;20(2):157-72 [9919436.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1127-35 [15564439.001]
  • [Cites] J Nutr. 2005 May;135(5):1331-5 [15867335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):7014-9 [15867144.001]
  • [Cites] Birth Defects Res A Clin Mol Teratol. 2005 Jul;73(7):478-80 [15959888.001]
  • [Cites] Environ Res. 2006 Jan;100(1):50-76 [16256977.001]
  • [Cites] Reprod Toxicol. 2006 Apr;21(3):307-12 [16257506.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S56-69 [16690810.001]
  • [Cites] Lab Anim. 2007 Jan;41(1):1-18 [17234046.001]
  • [Cites] Environ Health Perspect. 2007 Jun;115(6):902-8 [17589598.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13056-61 [17670942.001]
  • [Cites] Environ Health Perspect. 2007 Oct;115(10):1467-73 [17938737.001]
  • [Cites] Environ Health Perspect. 2008 Mar;116(3):389-93 [18335108.001]
  • [Cites] Nature. 1999 Oct 21;401(6755):763-4 [10548101.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12729-34 [11070086.001]
  • [Cites] J Nutr. 2001 Feb;131(2):354S-60S [11160560.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Exp Biol Med (Maywood). 2001 Dec;226(11):978-81 [11743132.001]
  • [Cites] Comp Med. 2003 Dec;53(6):607-15 [14727808.001]
  • [Cites] Reprod Toxicol. 2004 May;18(3):399-406 [15082075.001]
  • [Cites] J Anim Sci. 1989 Jul;67(7):1824-40 [2670873.001]
  • [Cites] Biol Reprod. 1990 Nov;43(5):751-61 [2291911.001]
  • [Cites] J Vet Diagn Invest. 1990 Oct;2(4):268-73 [2151311.001]
  • [Cites] Endocrinology. 1992 Jun;130(6):3184-90 [1375894.001]
  • [Cites] Biol Reprod. 1992 Nov;47(5):723-9 [1477199.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]
  • [Cites] Biol Reprod. 1995 Nov;53(5):1198-207 [8527526.001]
  • [Cites] Environ Health Perspect. 1995 Oct;103 Suppl 7:83-7 [8593881.001]
  • [Cites] Clin Chem. 1996 Jun;42(6 Pt 1):955-64 [8665689.001]
  • [Cites] Med Sci Monit. 2002 Dec;8(12):RA282-92 [12503048.001]
  • [Cites] Clin Chem. 1997 May;43(5):850; author reply 852 [9166244.001]
  • (PMID = 18335098.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES011283; United States / NIGMS NIH HHS / GM / T32 GM008396; United States / NIEHS NIH HHS / ES / ES11283
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Phytoestrogens; 4TI98Z838E / Estradiol
  • [Other-IDs] NLM/ PMC2265041
  • [Keywords] NOTNLM ; casein / estradiol / fat / glucose tolerance / leptin / metabolic syndrome / obesity / puberty / reproductive organs / soy
  •  go-up   go-down


50. Bhattacharya A, Rahman MM, McCarter R, O'Shea M, Fernandes G: Conjugated linoleic acid and chromium lower body weight and visceral fat mass in high-fat-diet-fed mice. Lipids; 2006 May;41(5):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This effect was accompanied by decreased serum leptin levels in CLA-fed and CLA + Cr-fed mice, and by higher energy expenditure (EE) and oxygen consumption (OC) in CLA + Cr-fed mice.
  • Serum levels of glucose, insulin, the pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6), as well as insulin resistance index (IRI), decreased with CLA, whereas CLA and Cr in combination had significant effects on insulin and IL-6 concentrations and IRI.
  • In summary, CLA + Cr decreased body weight and fat mass in high-fat-diet-fed mice, which may be associated with decreased leptin levels and higher EE and OC.
  • [MeSH-minor] Adiponectin / blood. Analysis of Variance. Animals. Dietary Fats / administration & dosage. Dietary Fats / pharmacology. Energy Metabolism / drug effects. Leptin / blood. Male. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Body Weight.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Rev. 2005 Aug;6(3):247-58 [16045640.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 15;323(2):679-84 [15369804.001]
  • [Cites] Diabetes. 2000 Sep;49(9):1534-42 [10969838.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):887-95 [15447895.001]
  • [Cites] Diabetes Res Clin Pract. 1996 Mar;31(1-3):27-35 [8792099.001]
  • [Cites] Lipids Health Dis. 2005 Jan 10;4:3 [15642120.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1199S-1206S [15159257.001]
  • [Cites] Biosci Biotechnol Biochem. 2002 Apr;66(4):916-20 [12036077.001]
  • [Cites] JAMA. 2004 Jun 16;291(23):2847-50 [15199035.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Apr;27(4):522-9 [12664086.001]
  • [Cites] J Nutr Biochem. 2004 Nov;15(11):680-7 [15590272.001]
  • [Cites] Wei Sheng Yan Jiu. 2000 Nov;29(6):370-1 [12520958.001]
  • [Cites] J Biomed Mater Res. 1996 Dec;32(4):655-61 [8953156.001]
  • [Cites] Biochim Biophys Acta. 2002 Apr 15;1581(3):89-99 [12020636.001]
  • [Cites] J Lipid Res. 2002 Sep;43(9):1400-9 [12235171.001]
  • [Cites] J Endocrinol. 1998 Oct;159(1):165-72 [9795354.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6):1118-25 [15159244.001]
  • [Cites] Aging (Milano). 1997 Feb-Apr;9(1-2):73-9 [9177588.001]
  • [Cites] Nutr Rev. 1998 Sep;56(9):266-70 [9763876.001]
  • [Cites] J Nutr. 2005 May;135(5):1124-30 [15867292.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2005 Feb;113(2):67-79 [15772897.001]
  • [Cites] Metabolism. 1998 Apr;47(4):396-400 [9550535.001]
  • [Cites] Diabetologia. 2004 Jun;47(6):1016-9 [15168020.001]
  • [Cites] Am J Physiol. 1998 Sep;275(3 Pt 2):R667-72 [9728060.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1153S-1158S [15159250.001]
  • [Cites] Diabetes Care. 2002 Sep;25(9):1516-21 [12196420.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 2004 Dec;50(6):416-21 [15895517.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1169S-1174S [15159253.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1164S-1168S [15159252.001]
  • [Cites] Lipids. 2002 Jul;37(7):725-8 [12216844.001]
  • [Cites] Diabetes. 2002 Jul;51(7):2037-44 [12086931.001]
  • [Cites] Annu Rev Nutr. 2002;22:505-31 [12055356.001]
  • [Cites] J Bone Miner Res. 2003 Jul;18(7):1206-16 [12854830.001]
  • [Cites] J Dairy Sci. 1995 Nov;78(11):2358-65 [8747326.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Diabetes Obes Metab. 2001 Aug;3 Suppl 1:S11-9 [11685824.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Apr 11;303(3):795-9 [12670481.001]
  • [Cites] Lipids. 1997 Aug;32(8):853-8 [9270977.001]
  • [Cites] Prog Lipid Res. 2004 Nov;43(6):553-87 [15522764.001]
  • [Cites] J Am Coll Nutr. 2005 Jun;24(3):200-9 [15930486.001]
  • [Cites] Public Health Nutr. 2004 Feb;7(1A):123-46 [14972057.001]
  • [Cites] Lipids. 2001 Jul;36(7):669-74 [11521964.001]
  • [Cites] Nutrition. 1999 Sep;15(9):720-2 [10467621.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38445-56 [16155293.001]
  • [Cites] JAMA. 1999 Oct 27;282(16):1519-22 [10546690.001]
  • [Cites] Nature. 2000 Apr 6;404(6778):635-43 [10766250.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Sep;285(3):E527-33 [12736161.001]
  • [Cites] J Nutr. 2003 Jun;133(6):1793-9 [12771319.001]
  • [Cites] Diabetes Res Clin Pract. 1995 Jun;28(3):179-84 [8529496.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jun;89(6):2665-71 [15181039.001]
  • [Cites] J Nutr. 2000 Oct;130(10 ):2471-7 [11015475.001]
  • [Cites] Am J Clin Nutr. 2004 Jun;79(6 Suppl):1132S-1136S [15159246.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2057-65 [11080069.001]
  • [Cites] Am J Clin Nutr. 1985 May;41(5 Suppl):1132-45 [3993620.001]
  • [Cites] J Nutr. 2002 Oct;132(10):2995-8 [12368384.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):860-1 [10622250.001]
  • [Cites] Diabetes. 2001 May;50(5):1149-57 [11334420.001]
  • [Cites] Nutrition. 2003 Jan;19(1):30-5 [12507636.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E563-9 [10710512.001]
  • [Cites] Am J Clin Nutr. 1981 Dec;34(12):2670-8 [7032273.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 17;310(2):562-6 [14521947.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6207-12 [15833818.001]
  • [Cites] Am J Vet Res. 1997 Jun;58(6):594-600 [9185964.001]
  • [Cites] Int J Obes. 1991 Sep;15 Suppl 2:109-15 [1794931.001]
  • [Cites] Obes Res. 2003 Mar;11(3):368-72 [12634431.001]
  • [Cites] J Nutr. 2005 Apr;135(4):778-84 [15795434.001]
  • [Cites] Metabolism. 1992 Jul;41(7):768-71 [1619996.001]
  • [Cites] Diabetes Care. 1994 Dec;17(12):1449-52 [7882815.001]
  • [Cites] Diabet Med. 2000 Sep;17(9):684-5 [11051290.001]
  • [Cites] Nutrition. 2004 Nov-Dec;20(11-12):1008-17 [15561492.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82 [9535724.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • [Cites] Lipids. 1999 Mar;34(3):235-41 [10230716.001]
  • (PMID = 16933788.001).
  • [ISSN] 0024-4201
  • [Journal-full-title] Lipids
  • [ISO-abbreviation] Lipids
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG023648; United States / NIA NIH HHS / AG / AG027562
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Dietary Fats; 0 / Leptin; 0 / Linoleic Acids, Conjugated; 0R0008Q3JB / Chromium
  •  go-up   go-down


51. Chen L, Li J, Zheng W, Zhang Y, Wu Y, Li L, Qian S, Xu W: The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. Leuk Lymphoma; 2007 Sep;48(9):1785-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) is characterized by the relentless accumulation of monoclonal B cells with the appearance of small mature lymphocytes and a characteristic CD5 and CD19 co-expression immunophenotype.
  • To investigate CLLU1 expression in CLL and explore the relationship between CLLU1 expression and alternative prognostic markers, we measured CLLU1 expression levels by semiquantitative RT-PCR in a cohort of 50 Chinese patients with CLL.
  • The expression levels of CLLU1 were significantly increased in B + C CLL patients at Binet stage compared with those at Binet stage A (P = 0.005).
  • Patients with unmutated IgVH genes expressed higher levels of CLLU1 than did those with IgVH mutations (P < 0.05).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Neoplasm Proteins / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1665-6 [17786698.001]
  • (PMID = 17786715.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLLU1 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Neoplasm Proteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


52. Al Maskari MY, Alnaqdy AA: Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis. Sultan Qaboos Univ Med J; 2006 Dec;6(2):27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between Serum Leptin Levels, Body Mass Index and Obesity in Omanis.
  • OBJECTIVE: To ascertain the relationship between serum leptin levels and related variables (weight, Body Mass Index (BMI) and fat percentage) in a group of Omani obese and non-obese healthy subjects.
  • METHODS: Leptin levels were assessed in serum samples from 35 obese Omanis and 20 non-obese healthy subjects.
  • RESULTS: There was a significant difference (p< 0.001) in serum leptin between the obese group (34.78 + 13.96 ng/ml) and the control non-obese subjects (10.6 ± 4.2 ng/ml).
  • Leptin levels were higher in females compared to males.
  • There was a significantly positive correlation between leptin levels in obese subjects with weight (p=0.002), body fat percentage (p=0.0001) and BMI (p=0.001).
  • CONCLUSIONS: We concluded that serum leptin levels are higher in the Omani obese group and correlate positively with body fatness and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3424-7 [8784109.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1632-4 [9141562.001]
  • [Cites] J Clin Invest. 1997 May 15;99(10):2398-404 [9153282.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4144-8 [9398729.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jun;83(6):2149-55 [9626154.001]
  • [Cites] Kidney Int. 1998 Oct;54(4):1267-75 [9767543.001]
  • [Cites] Horm Res. 1998;50(6):297-302 [9973668.001]
  • [Cites] Adv Physiol Educ. 2003 Dec;27(1-4):70-7 [12760843.001]
  • [Cites] Diabet Med. 2002 Nov;19(11):954-7 [12421434.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Sep;81(9):3419-23 [8784108.001]
  • [Cites] Ann Saudi Med. 2000 Mar;20(2):113-8 [17322705.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1980-5 [12031989.001]
  • [Cites] Physiol Res. 2001;50(5):443-59 [11702849.001]
  • [Cites] Atherosclerosis. 2001 Aug;157(2):495-503 [11472752.001]
  • [Cites] Cesk Fysiol. 2001 Feb;50(1):25-30 [11268559.001]
  • [Cites] East Mediterr Health J. 1999 Jan;5(1):14-20 [10793776.001]
  • [Cites] Nutrition. 1999 Nov-Dec;15(11-12):829-33 [10575656.001]
  • [Cites] J Mol Endocrinol. 1999 Apr;22(2):173-84 [10194520.001]
  • [Cites] Int J Obes Relat Metab Disord. 1999 Feb;23 Suppl 1:22-8 [10193858.001]
  • [Cites] Nat Med. 1995 Nov;1(11):1155-61 [7584987.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Diabet Med. 1995 Dec;12(12):1122-5 [8750224.001]
  • (PMID = 21748132.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3074914
  • [Keywords] NOTNLM ; Body Mass Index / Body weight / Leptin / Obesity / Oman
  •  go-up   go-down


53. Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC: Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Dec;50(12):1977-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) cells are susceptible to oxidative stress.
  • A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and small lymphocytic lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Metalloporphyrins / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Immunoblotting. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860624.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Metalloporphyrins; 6433A42F4F / motexafin gadolinium; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


54. Di Carlo C, Tommaselli GA, Gargano V, Sammartino A, Bifulco G, Tauchmanova L, Colao A, Nappi C: Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause; 2007 Jan-Feb;14(1):38-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women.
  • OBJECTIVE: The aim of this study was to evaluate the effects of estrogen-progestin therapy on serum levels of receptor-activating nuclear factor kappabeta ligand (RANKL), osteoprotegerin, osteocalcin, leptin, and ghrelin in a cross-sectional study of 99 healthy postmenopausal women conducted at the Menopause Clinic of our department.
  • Serum leptin levels were significantly lower in group B than in group A, whereas ghrelin was significantly higher in group B than in group A.
  • Similarly, although several reports suggest that leptin and ghrelin are involved in bone metabolism, we could not detect any important correlation of these two hormones with bone metabolism or bone status in treated and untreated postmenopausal women.
  • [MeSH-minor] Administration, Cutaneous. Bone Density / drug effects. Cross-Sectional Studies. Female. Finger Phalanges / ultrasonography. Ghrelin. Humans. Leptin / blood. Middle Aged. Osteocalcin / blood. Osteoporosis / prevention & control. Peptide Hormones / blood. Receptors, Leptin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Menopause. 2007 Jan-Feb;14(1):7-9 [17194959.001]
  • (PMID = 17075432.001).
  • [ISSN] 1072-3714
  • [Journal-full-title] Menopause (New York, N.Y.)
  • [ISO-abbreviation] Menopause
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Ghrelin; 0 / Leptin; 0 / Osteoprotegerin; 0 / Peptide Hormones; 0 / Progestins; 0 / RANK Ligand; 0 / Receptors, Leptin; 0 / leptin receptor, human; 104982-03-8 / Osteocalcin
  •  go-up   go-down


55. Argentou M, Tiniakos DG, Karanikolas M, Melachrinou M, Makri MG, Kittas C, Kalfarentzos F: Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. Obes Surg; 2009 Sep;19(9):1313-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery.
  • BACKGROUND: Leptin, adiponectin, and resistin are adipokines linked to the development of insulin resistance, which plays a central role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
  • We aimed to define adipokine serum levels in severely obese patients undergoing bariatric surgery and to correlate these with anthropometric and metabolic variables, liver function tests, and histopathological parameters of NAFLD and nonalcoholic steatohepatitis (NASH).
  • Serum leptin, adiponectin, and resistin levels were measured, and histology was assessed using Brunt's and Kleiner's scoring systems.
  • RESULTS: Waist/hip ratio was significantly higher in men (p = 0.0001), and leptin (p = 0.036) and adiponectin (p = 0.0001) serum levels were higher in women.
  • In NAFLD patients, serum adiponectin was negatively correlated with activity grade and fibrosis stage, resistin was negatively correlated with steatosis grade (p = 0.033), while leptin was not related to histology.
  • Leptin/adiponectin ratio showed positive association with stage (p = 0.044).
  • In the subgroup of NASH patients, adiponectin was negatively correlated only with stage (p = 0.01), while there was no correlation between leptin, resistin, or leptin/adiponectin and histology.
  • CONCLUSIONS: Serum adiponectin and resistin levels are related to liver histology in bariatric patients and may be indicative of the histological severity of NAFLD and the extent of hepatic steatosis, respectively.
  • Serum leptin levels are not informative of underlying liver histology in severely obese patients.

  • MedlinePlus Health Information. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 1972 Jun;18(6):499-502 [4337382.001]
  • [Cites] Am J Gastroenterol. 1999 Sep;94(9):2467-74 [10484010.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S15-21 [17331160.001]
  • [Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Am J Gastroenterol. 2006 Nov;101(11):2629-40 [16952281.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5122-5 [16968796.001]
  • [Cites] Dig Dis Sci. 2008 Apr;53(4):1088-92 [17934820.001]
  • [Cites] Nutr Rev. 2007 Jun;65(6 Pt 2):S57-63 [17605315.001]
  • [Cites] Hepatology. 2008 Feb;47(2):484-92 [18220286.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2008 May;11(3):267-74 [18403923.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Mar;7(2):195-205 [17331066.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1593-9 [17294310.001]
  • [Cites] Hepatology. 2002 Aug;36(2):403-9 [12143049.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Jun;64(6):679-83 [16712671.001]
  • [Cites] Curr Opin Lipidol. 2006 Apr;17(2):170-5 [16531754.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):934-45 [16952562.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Obes Surg. 2005 Feb;15(2):228-37 [15802066.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1848-52 [16697746.001]
  • [Cites] Obes Surg. 2008 Nov;18(11):1430-7 [18500507.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2771-6 [14687831.001]
  • [Cites] Liver Int. 2006 Mar;26(2):151-6 [16448452.001]
  • [Cites] Obes Surg. 2005 Mar;15(3):310-5 [15826462.001]
  • [Cites] J Hepatol. 2006 Oct;45(4):600-6 [16899321.001]
  • [Cites] Mediators Inflamm. 2006;2006(6):34295 [17392582.001]
  • [Cites] JAMA. 2001 May 16;285(19):2486-97 [11368702.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Mar 1;27(5):412-21 [18081738.001]
  • [Cites] Hepatology. 2005 Aug;42(2):490-2 [15977205.001]
  • [Cites] Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi [17544979.001]
  • [Cites] Obes Surg. 2006 Oct;16(10):1351-8 [17059746.001]
  • [Cites] J Hepatol. 2004 Dec;41(6):943-9 [15582127.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3498-504 [15797948.001]
  • [Cites] Obes Surg. 2006 Dec;16(12):1584-93 [17217634.001]
  • [Cites] Hepatology. 2006 Feb;43(2 Suppl 1):S99-S112 [16447287.001]
  • [Cites] Scand J Gastroenterol. 2008;43(9):1128-36 [18609175.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1512-6 [17708287.001]
  • [Cites] Hepatology. 2003 May;37(5):1202-19 [12717402.001]
  • [Cites] Hepatology. 2007 Aug;46(2):582-9 [17661414.001]
  • [Cites] Hepatology. 2007 Sep;46(3):716-22 [17659597.001]
  • [Cites] Gut. 2005 Jan;54(1):117-21 [15591515.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1844-8 [15070954.001]
  • [Cites] Am J Gastroenterol. 2007 Feb;102(2):399-408 [17311652.001]
  • [Cites] Obes Surg. 2000 Aug;10(4):378-9 [11202981.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1682-98 [18471547.001]
  • [Cites] Med Clin North Am. 2007 Nov;91(6):1125-49, ix [17964913.001]
  • [Cites] J Appl Physiol (1985). 1988 Feb;64(2):529-34 [3372410.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Mar;91(3):1081-6 [16394091.001]
  • [Cites] J Hepatol. 2008 May;48(5):829-34 [18321606.001]
  • [Cites] Scand J Gastroenterol. 2006 May;41(5):566-72 [16638699.001]
  • [Cites] Am J Gastroenterol. 2007 Sep;102(9):1931-8 [17511754.001]
  • [Cites] J Pediatr Endocrinol Metab. 2004 Aug;17(8):1069-75 [15379417.001]
  • [Cites] Curr Opin Gastroenterol. 2007 Mar;23(2):193-8 [17268250.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1175-83 [16231364.001]
  • [Cites] Eur J Endocrinol. 2005 Jan;152(1):113-8 [15762194.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):837-47 [17951208.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 19693638.001).
  • [ISSN] 0960-8923
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines
  •  go-up   go-down


56. Srivastava RK, Krishna A: Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi. Reproduction; 2007 Jan;133(1):165-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adiposity associated rise in leptin impairs ovarian activity during winter dormancy in Vespertilionid bat, Scotophilus heathi.
  • The aim of the study was to evaluate the seasonal variation in serum leptin levels in a natural population of the female bat, Scotophilus heathi and their relationship to the changes in the body mass, serum insulin level, and ovarian activity.
  • Circulating leptin level varied significantly over the season and correlated positively with the changes in body mass, and circulating insulin and androstenedione (A4) levels.
  • Circulating leptin concentrations showed two peaks; one coincides with the maximum fat accumulation prior to winter dormancy, whereas the second shorter peak coincides with late pregnancy.
  • The in vivo study in S. heathi showed that the increased circulating leptin level during winter dormancy coincides with the decreased expression of ovarian steroidogenic acute regulatory (StAR) protein, and low circulating estradiol (E2) level.
  • At the same time, increased circulating leptin level coincides with increased expression of ovarian insulin receptor and high circulating A4 level.
  • The low circulating leptin level during preovulatory period coincides with the increase in StAR protein but decrease in insulin receptor protein.
  • The in vitro study confirmed the in vivo observations of inhibitory effect of leptin on LH induced StAR expression and E2 production, whereas the stimulatory effect of leptin (high dose) on LH induced expression of insulin receptor protein and A4 production.
  • However, pharmacological dose of leptin produced inhibitory effect on the expression of insulin receptor protein.
  • The results of the present study thus suggest that high circulating leptin level during winter dormancy promotes adiposity and impairs ovarian activity by suppressing StAR-mediated E2 production as well as by enhancing insulin receptor-mediated A4 synthesis thereby contributing anovulatory condition of delayed ovulation in S. heathi.
  • [MeSH-major] Adiposity / physiology. Chiroptera / metabolism. Hibernation / physiology. Leptin / blood. Ovary / metabolism

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17244743.001).
  • [ISSN] 1470-1626
  • [Journal-full-title] Reproduction (Cambridge, England)
  • [ISO-abbreviation] Reproduction
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin; 0 / Leptin; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 409J2J96VR / Androstenedione; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


57. Farfsing A, Engel F, Seiffert M, Hartmann E, Ott G, Rosenwald A, Stilgenbauer S, Döhner H, Boutros M, Lichter P, Pscherer A: Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia. Leukemia; 2009 Nov;23(11):2018-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.
  • The two B-cell non-Hodgkin's lymphoma entities, chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), show recurrent chromosomal gains of 3q25-q29, 12q13-q14 and 18q21-q22.
  • The aim of this study was to identify genes, located within these gained regions, which control cell death and cell survival of MCL and CLL cancer cells.
  • Blood samples collected from 18 patients with CLL and 6 patients with MCL, as well as 6 cell lines representing both malignancies were analyzed by gene expression profiling.
  • We performed a limited RNA interference screening with these candidates to identify genes affecting cell survival.
  • CCDC50 (coiled coil domain containing protein 50), SERPINI2 and SMARCC2 mediated a reduction of cell viability in primary CLL cells as well as in cell lines.
  • [MeSH-major] Intracellular Signaling Peptides and Proteins / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, Mantle-Cell / genetics. RNA, Small Interfering
  • [MeSH-minor] Bone Marrow Cells / cytology. Cell Line, Tumor. Cell Survival / physiology. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Genetic Testing. Genomics. Humans. Kidney / cytology. NF-kappa B / metabolism. Neoplasm Proteins / genetics. Protein Structure, Tertiary. Serpins / genetics. Transcription Factors / genetics. Transfection

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19641524.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCDC50 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / NF-kappa B; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / SERPINI2 protein, human; 0 / SMARCC2 protein, human; 0 / Serpins; 0 / Transcription Factors
  •  go-up   go-down


58. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ: Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol; 2006 May 20;24(15):2343-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
  • PATIENTS AND METHODS: An electronic database search of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who presented at The University of Texas M.D.
  • RESULTS: Of the 3,986 patients with CLL/SLL, 204 patients (5.1%) had possible RS, and 148 patients (3.7%) had biopsy- or fine-needle aspiration-proven RS.
  • A total of 20 patients underwent stem-cell transplantation (SCT).
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Transformation, Neoplastic. Combined Modality Therapy. Disease Progression. Female. Health Status Indicators. Humans. Immunologic Factors / therapeutic use. Incidence. Male. Middle Aged. Prognosis. Remission Induction. Risk. Rituximab. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710033.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


59. Zemanová M, Petruzelka L, Pazdrová G, Haluzík M, Novák F, Svobodník A: [Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer]. Cas Lek Cesk; 2005;144(12):811-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in leptin, leptin receptor and fatty acids levels during chemoradiotherapy for oesophageal cancer].
  • Leptin, a protein produced by adipocytes, is an important signalling molecule in energy regulation, metabolism of fatty acids and it can also augment tumour growth of various cancer cell lines.
  • METHODS AND RESULTS: In this study we examined the nutritional status (pre-treatment weight-loss, actual weight, body mass index), serum levels of leptin, soluble leptin receptor, TNF-alpha, IGF-1 and plasma phosphatidyl-cholin fatty acids before the beginning of treatment, after the onset of treatment and shortly before its completion.
  • Concomitant chemoradiation led to transient elevation of serum leptin level despite the weight loss during chemoradiotherapy.
  • [MeSH-major] Esophageal Neoplasms / blood. Fatty Acids / blood. Leptin / blood. Receptors, Cell Surface / blood
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Insulin-Like Growth Factor I / analysis. Male. Middle Aged. Phosphatidylcholines / chemistry. Receptors, Leptin. Tumor Necrosis Factor-alpha / analysis. Weight Loss

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389753.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Leptin; 0 / Phosphatidylcholines; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / Tumor Necrosis Factor-alpha; 0 / leptin receptor, human; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


60. Korotkova M, Gabrielsson BG, Holmäng A, Larsson BM, Hanson LA, Strandvik B: Gender-related long-term effects in adult rats by perinatal dietary ratio of n-6/n-3 fatty acids. Am J Physiol Regul Integr Comp Physiol; 2005 Mar;288(3):R575-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that the ratio of n-6 to n-3 polyunsaturated fatty acids (PUFA) in the maternal diet affects serum leptin levels and growth of the suckling pups.
  • The aim of the present study was to investigate the long-term effects of various ratios of the dietary n-6 and n-3 PUFA during the perinatal period on serum leptin, insulin, and triacylglycerol, as well as body growth in the adult offspring.
  • At 3 wk of age, the n-6/n-3 PUFA ratios in the serum phospholipids of the offspring were 2.5, 8.3, and 17.5, respectively.
  • At the 28th postnatal wk, mean body weight and fasting insulin levels were significantly increased in the rats fed the n-6/n-3 diet perinatally compared with the other groups.
  • The systolic blood pressure and serum triacylglycerol levels were only increased in adult male rats of the same group.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Am J Physiol Regul Integr Comp Physiol. 2006 Nov;291(5):R1564
  • (PMID = 15699360.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Fatty Acids, Omega-3; 0 / Fatty Acids, Omega-6; 0 / Insulin; 0 / Phospholipids; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


61. Pauwels NS, Bracke KR, Maes T, Pilette C, Joos GF, Brusselle GG: The role of interleukin-6 in pulmonary and systemic manifestations in a murine model of chronic obstructive pulmonary disease. Exp Lung Res; 2010 Oct;36(8):469-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased levels of interleukin-6 (IL-6) have been demonstrated in sputum and serum of COPD patients.
  • Wild-type (WT) and IL-6 knockout (KO) mice were exposed subacutely (4 weeks) and chronically (24 weeks) to air or cigarette smoke (CS).
  • Subacute and chronic CS exposure significantly increased pulmonary IL-6 mRNA expression in lung tissue and IL-6 protein levels in bronchoalveolar lavage fluid of WT mice.
  • Remarkably, air-exposed IL-6 KO mice have lower body weight, serum leptin levels, and adipose tissue mass compared to air-exposed WT mice.
  • [MeSH-minor] Adipose Tissue, White / drug effects. Adipose Tissue, White / metabolism. Animals. Bronchoalveolar Lavage Fluid / cytology. Cell Count. Cytokines / genetics. Cytokines / metabolism. Disease Models, Animal. Gene Expression / drug effects. Leptin / genetics. Leptin / metabolism. Lymphocytes / drug effects. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Mice. Mice, Knockout. RNA, Messenger / metabolism. Smoking / adverse effects. Tobacco Smoke Pollution / adverse effects

  • MedlinePlus Health Information. consumer health - COPD.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20939756.001).
  • [ISSN] 1521-0499
  • [Journal-full-title] Experimental lung research
  • [ISO-abbreviation] Exp. Lung Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Leptin; 0 / RNA, Messenger; 0 / Tobacco Smoke Pollution
  •  go-up   go-down


62. Aurangzeb B, Leach ST, Lemberg DA, Day AS: Nutritional status of children with coeliac disease. Acta Paediatr; 2010 Jul;99(7):1020-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The nutritional status of newly diagnosed CD was assessed by anthropometry, Bioelectrical Impedance and serum leptin levels, and contrasted to age and gender matched controls.
  • Mean height and weight for age, other nutritional parameters and serum leptin did not differ between the groups.
  • Serum leptin correlated with BMI in both groups.
  • Variations in nutrition (under to overnutrition) may be seen at diagnosis, without relationship to the presence of symptoms.
  • Leptin levels were not altered specifically in the setting of CD.
  • [MeSH-minor] Adolescent. Anthropometry. Case-Control Studies. Child. Child, Preschool. Electric Impedance. Female. Humans. Infant. Leptin / blood. Male. Nutrition Assessment

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Child Nutrition.
  • MedlinePlus Health Information. consumer health - Toddler Nutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178518.001).
  • [ISSN] 1651-2227
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


63. Akinci M, Kosova F, Cetin B, Aslan S, Ari Z, Cetin A: Leptin levels in thyroid cancer. Asian J Surg; 2009 Oct;32(4):216-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin levels in thyroid cancer.
  • BACKGROUND: Leptin has physiological roles in multiple systems, and has possible effects on several carcinogenesis steps.
  • The aim of this study was to investigate the leptin levels in thyroid papillary carcinoma (TPC) patients.
  • TPC patients had a bilateral total thyroidectomy operation and their leptin levels were measured before and 20 days after the operation.
  • RESULTS: Serum leptin levels of TPC patients were higher than in control group subjects (21.15 +/- 14.12 ng/mL vs. 9.89 +/- 0.21 ng/mL, p < 0.05).
  • The leptin levels decreased after total thyroidectomy (13.92 +/- 10.55 ng/mL) compared to prethyroidectomy levels (22.94 +/- 14.67 ng/mL) in 34 patients who came to the follow-up visit (p < 0.05).
  • However, the decreased post-thyroidectomy levels of leptin were still statistically significantly higher than the control group levels.
  • Multivariate regression analysis showed that the leptin levels in TPC patients were not related to age, menopausal status or pathologic occult status but were directly related to the cancer group.
  • CONCLUSION: Leptin levels were elevated in thyroid cancer, decreased after total thyroidectomy, and might be associated with thyroid papillary carcinogenesis.

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892624.001).
  • [ISSN] 0219-3108
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


64. Jaleel F, Jaleel A, Aftab J, Rahman MA: Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease. Med Sci Monit; 2006 Sep;12(9):CR382-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin and blood lipid levels in postmenopausal diabetic women with and without complication of ischemic heart disease.
  • BACKGROUND: Recent studies have provided evidence that leptin has significant effects on vascular development and repair.
  • The aim was to determine the levels of leptin and lipid profile in diabetic postmenopausal women with and without the complication of ischemic heart disease and to develop correlation between them.
  • Moreover, the relationship between leptin levels and extent of ischemic changes were determined.
  • The first group comprised normal healthy controls, the second diabetic type 2 patients with no history of ischemic heart disease (I1ID), and the third diabetic patients with IHD.
  • Serum leptin levels were determined by a Kit obtained from DRG and samples were analyzed on ELISA.
  • RESULTS: The results show that leptin and serum lipid levels increased significantly in diabetic patients with IHD compared with diabetic patients without IHD as well as normal subjects.
  • Moreover; the sertum leptin level increased significantly in the diabetic patients with IHD who had positive findings in myocardial perfusion scan compared with those having negative findings.
  • CONCLUSIONS: Hyperleptinemia in diabetic patients shows that leptin contributes to the development of cardiovascular disease in diabetic patients.
  • [MeSH-major] Diabetes Mellitus, Type 2 / blood. Hyperlipidemias / complications. Leptin / blood. Myocardial Ischemia / etiology. Postmenopause / blood

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16940932.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Leptin; 0 / Lipids
  •  go-up   go-down


65. Jalil A, Amir S, Majeed R, Jalil F: Circulating leptin levels in elderly subjects with and without cerebrovasular disease. J Coll Physicians Surg Pak; 2010 May;20(5):350-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating leptin levels in elderly subjects with and without cerebrovasular disease.
  • Serum concentrations of leptin was investigated in 40 patients with ischemic stroke, in context of the size of the lesion and also in 40 non-diseased controls, matched according to age, gender and waist hip ratio.
  • Serum leptin concentrations were determined in ng/ml with ELISA and computer tomography (CT) scan was performed in patients to estimate lesion size in cms.
  • Serum leptin concentrations were found to be significantly higher (p < 0.001) in stroke patients (51.61+1.39), compared with controls (37.76+1.207).
  • Moreover, positive correlation (r=0.93) existed between serum leptin level and infarction size in patients with stroke.
  • [MeSH-major] Cerebrovascular Disorders / blood. Leptin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20642935.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Leptin
  •  go-up   go-down


66. Flanagan MB, Sathanoori M, Surti U, Soma L, Swerdlow SH: Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens. Am J Clin Pathol; 2008 Oct;130(4):620-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens.
  • Cytogenetic fluorescence in situ hybridization (FISH) panels are a major prognostic tool in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but few data exist on using paraffin-embedded extramedullary tissue biopsy specimens for these purposes.
  • Isolated whole nuclei were extracted from 20 paraffin-embedded tissue biopsy specimens with CLL/SLL and analyzed using a standard CLL FISH panel.
  • Cytogenetic FISH studies using paraffin-embedded tissue biopsy specimens in CLL/SLL had a high yield and, with 1 exception, demonstrated a profile similar to cases diagnosed in PB/BM.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Paraffin Embedding

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794056.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Ioannou GN, Weiss NS, Kearney DJ: Is Helicobacter pylori seropositivity related to body mass index in the United States? Aliment Pharmacol Ther; 2005 Mar 15;21(6):765-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Helicobacter pylori infection may decrease serum ghrelin and increase gastric leptin levels, which may, in turn, decrease body mass index.
  • METHODS: Serum H. pylori and cytotoxin-associated gene product A (CagA) antibody levels were measured on 6724 adult participants of the third National Health and Nutrition Examination Survey (1988-91).
  • We also investigated whether H. pylori/cytotoxin-associated gene product A antibody status was associated with fasting serum leptin levels.
  • RESULTS: H. pylori/CagA antibody status was not associated with obesity (body mass index > or = 30 kg/m(2)) [adjusted odds ratio (OR) 1.2, 95% CI: 0.9-1.6 comparing (+/+) to (-/-) and adjusted OR 1.1, 95% CI: 0.8-1.5 comparing (+/-) to (-/-)], overweight (body mass index 25 to <30 kg/m(2)) [adjusted OR 1.0, 95% CI: 0.7-1.2 comparing (+/+) to (-/-) and adjusted OR 1.0, 95% CI: 0.8-1.3 comparing (+/-) to (-/-)], or fasting serum leptin level in the USA population.
  • CONCLUSIONS: H. pylori seropositivity and CagA antibody status are not associated with body mass index or fasting serum leptin level.
  • [MeSH-minor] Adult. Aged. Antigens, Bacterial / blood. Bacterial Proteins / blood. Enzyme-Linked Immunosorbent Assay. Epidemiologic Methods. Female. Humans. Leptin / blood. Male. Middle Aged. Obesity / blood. Obesity / epidemiology. Obesity / ethnology. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771763.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Leptin; 0 / cagA protein, Helicobacter pylori
  •  go-up   go-down


68. Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Bárány P: Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis; 2005 Oct;46(4):628-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
  • Furthermore, the adipokine leptin stimulates human erythroid development in vitro.
  • In the present study, we investigate the impact of fat mass and leptin level on epoetin sensitivity in patients with ESRD.
  • Body composition was analyzed by dual-energy X-ray absorptiometry and correlated with serum markers of inflammation and leptin (analyzed by enzyme-linked immunosorbent assays), as well as with epoetin dose, in international units administered per week (IU/wk).
  • To correct for differences in body mass and hemoglobin (Hb) levels, epoetin sensitivity was approximated as epoetin/Hb ratio, ie, epoetin dose per unit of Hb (IU/wk/g/dL) and epoetin/Hb/kg ratio, ie, epoetin dose per unit of Hb and kilogram of patient body weight (IU/wk/Hb/kg).
  • The 3 groups had significantly different serum levels of high-sensitivity C-reactive protein (hsCRP; median, 8.6 versus 3.1 and 8.0 mg/L, respectively; P < 0.05), neopterin (median, 112.4 versus 94.3 and 96.1 ng/L, respectively; P < 0.05), and IL-6 (median, 6.8 versus 4.1 and 6.5 ng/mL, respectively; P < 0.05).
  • Significant between-group differences also were found in fat mass and leptin levels (median, 14.8 versus 10.5 and 7.9 ng/mL, respectively; P = 0.02).
  • In univariate analyses, significant relationships between epoetin sensitivity indices, leptin levels, and levels of the inflammatory markers hsCRP and IL-6 were found.
  • In a multivariate stepwise regression model, log ferritin, parathyroid hormone, log leptin, log IL-6, and polycystic kidney disease were significantly associated with the epoetin/Hb ratio.
  • CONCLUSION: The present study shows that leptin level may be a predictor of epoetin sensitivity.
  • Although truncal fat is associated with secretion of proinflammatory cytokines, this secretion appears not to have inhibitory effects on epoetin sensitivity in the presence of high leptin levels.
  • [MeSH-major] Adipose Tissue / pathology. Anemia / drug therapy. Body Composition. Erythropoiesis / drug effects. Erythropoietin / analogs & derivatives. Kidney Failure, Chronic / complications. Leptin / blood

  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Kidney Dis. 2006 Feb;47(2):371; author reply 372 [16431269.001]
  • (PMID = 16183417.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Interleukin-6; 0 / Leptin; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa; 9007-41-4 / C-Reactive Protein; 9007-73-2 / Ferritins
  •  go-up   go-down


69. Farmer PL, Bailey DJ, Burns BF, Day A, LeBrun DP: The reliability of lymphoma diagnosis in small tissue samples is heavily influenced by lymphoma subtype. Am J Clin Pathol; 2007 Sep;128(3):474-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reliability of lymphoma diagnosis in small tissue samples is heavily influenced by lymphoma subtype.
  • A specific pathologic diagnosis is important in malignant lymphoma because the diverse disease subtypes require tailored approaches to clinical management.
  • Reliance on small samples obtained with cutting needles has been advocated as a less invasive alternative to using larger, excised samples.
  • Although published studies have demonstrated the safety and apparent sufficiency of this approach in informing clinical care, none have systematically determined the accuracy of pathologic lymphoma subtyping based on very small samples.
  • We used a tissue microarray representing 67 cases of malignant lymphoma and 17 samples of nonneoplastic lymphoid tissue to model lymphoma diagnosis in small samples.
  • Overall, 73.8% of the cases were diagnosed with a level of confidence deemed sufficient for directing clinical management; 85.9% of these diagnoses were accurate.
  • Small cell lymphomas with highly distinctive immunophenotypes, including small lymphocytic, mantle cell, and T-lymphoblastic lymphoma, were recognized most consistently and accurately in the small samples.
  • In contrast, follicular lymphoma and marginal zone lymphoma were especially difficult.
  • Our results indicate that the reliability of lymphoma diagnoses based on small samples is heavily influenced by lymphoma subtype.
  • [MeSH-major] Lymphoma / diagnosis. Tissue Array Analysis / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17709322.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Lin TS: Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies. Clin Lymphoma Myeloma; 2008 Aug;8 Suppl 4:S137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
  • Alkylating agents and purine analogues have been the mainstays of therapy for chronic lymphocytic leukemia (CLL) for decades.
  • (1) the alkylator bendamustine, (2) the cyclin-dependent kinase inhibitor flavopiridol, (3) the immunomodulating drug lenalidomide, (4) the bcl-2 antisense oligonucleotide oblimersen, and (5) the Bcl-2 small-molecule inhibitor obatoclax.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18952544.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Flavonoids; 0 / Nitrogen Mustard Compounds; 0 / Piperidines; 0 / Pyrroles; 0 / Thionucleotides; 0 / obatoclax; 45AD6X575G / alvocidib; 4Z8R6ORS6L / Thalidomide; 85J5ZP6YSL / oblimersen; 981Y8SX18M / Bendamustine Hydrochloride; F0P408N6V4 / lenalidomide
  • [Number-of-references] 30
  •  go-up   go-down


71. Chiu BC, Soni L, Gapstur SM, Fought AJ, Evens AM, Weisenburger DD: Obesity and risk of non-Hodgkin lymphoma (United States). Cancer Causes Control; 2007 Aug;18(6):677-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and risk of non-Hodgkin lymphoma (United States).
  • OBJECTIVE: Few studies have explored the potential association between body mass index (BMI) and non-Hodgkin lymphoma (NHL) according to histologic subtypes, or have evaluated BMI at different periods in the subject's life, and the results of these studies have been inconsistent.
  • Obesity at ages 40-49 years was also associated with a higher risk of small lymphocytic lymphoma (OR=4.5; 95% CI=1.5-13.3), diffuse large B-cell NHL (OR=1.8; 95% CI=0.9-3.9) and follicular NHL (OR=1.8; 95% CI=0.9-3.5).
  • Obesity at ages 40-49 years is also associated with a higher risk of NHL overall, and particularly small lymphocytic, follicular, and diffuse large B-cell NHL.
  • [MeSH-major] Body Mass Index. Lymphoma, Non-Hodgkin / etiology. Obesity / complications


72. Bi R, Lin DM, Han YL, Lu J, Xue LY, Zheng S, Wang MR, Lü N: [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Nov;38(11):733-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of interphase fluorescence in situ hybridization in the diagnosis of lymphoma].
  • OBJECTIVE: To investigate the feasibility of interphase FISH in the routine clinicopathological practice and its values in the differential diagnosis of lymphomas.
  • METHODS: A total of 74 fresh tissue samples clinically suspicious of lymphoma were investigated by FISH using three probes including IgH/bcl-2, IgH/CCND1 and API2/MALT1, corresponding the translocation t(14;18), t(11;14) and t(11;18) respectively.
  • The results of FISH were analyzed and compared with the histopathologic diagnosis.
  • RESULTS: Histological evaluation eventually confirmed that there were 62 cases of lymphoma and 12 cases of reactive lymphoid processes.
  • The translocations were detected in 7 cases in 62 cases of lymphoma: 3 demonstrated t(14;18) including 2 cases of follicular lymphomas and 1 nodular sclerosing Hodgkin lymphoma.
  • Four cases had t(11;14) including mantle cell lymphoma (2 cases), follicular lymphoma (1 case) and small cell lymphoma (1 case).
  • Amplification or loss of regional genes was seen more often in malignant than in the benign cases.
  • CONCLUSION: Interphase FISH offers useful ancillary technology that plays an important role in differential diagnosis and classification of lymphoma.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Lymphoma / diagnosis. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 18. Diagnosis, Differential. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / genetics. Hodgkin Disease / pathology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / pathology. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079011.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


73. Hirosawa M, Minata M, Harada KH, Hitomi T, Krust A, Koizumi A: Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin. Biochem Biophys Res Commun; 2008 Jun 27;371(2):320-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ablation of estrogen receptor alpha (ERalpha) prevents upregulation of POMC by leptin and insulin.
  • Ovariectomized diabetic (AFO) and nondiabetic (B6FO) mice had significantly lower food intake and elevated serum leptin levels.
  • ERaKOAkt and ERaKO mice also increased serum leptin concentrations, while hypoinsulinemia was observed in ERaKOAkt and hyperinsulinemia in ERaKO mice.
  • RT-PCR showed a significant attenuation of POMC expression in both ERaKOAkt and ERaKO mice, irrespective of the elevated leptin serum levels or hyperinsulinemia, while elevated serum leptin levels in AFO and B6FO mice upregulated POMC gene expression.
  • These results indicate that ERalpha plays an essential role in leptin- and insulin-stimulated upregulation of the POMC gene.
  • [MeSH-major] Estrogen Receptor alpha / physiology. Gene Expression Regulation. Hyperphagia / genetics. Insulin / metabolism. Leptin / metabolism. Pro-Opiomelanocortin / genetics

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439911.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Insulin; 0 / Leptin; 66796-54-1 / Pro-Opiomelanocortin
  •  go-up   go-down


74. Wang HC, Yang YK, Chen PS, Lee IH, Yeh TL, Lu RB: Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males. Neuropsychobiology; 2007;56(4):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased plasma leptin in antipsychotic-naïve females with schizophrenia, but not in males.
  • BACKGROUND: Metabolic abnormalities, including insulin resistance and increased leptin levels, were noted in patients with schizophrenia who had received antipsychotics.
  • In this study, we examined the leptin levels of antipsychotic-naïve schizophrenic patients.
  • Serum leptin levels of the healthy controls and antipsychotic-naïve patients were compared.
  • The relationships between leptin level and gender, Positive and Negative Syndrome Scale score, and duration of illness were analyzed by Spearman's correlation.
  • RESULTS: Compared with sex-, age- and BMI-matched subjects, the female schizophrenic patients had elevated serum leptin levels.
  • In the male patients, the results of this preliminary study also revealed a positive correlation between leptin levels and the Aggression Risk Profile subscale of the PANSS.
  • CONCLUSION: This preliminary study suggests possible gender-specific leptin dysregulation in antipsychotic-naïve schizophrenic patients.
  • [MeSH-major] Leptin / blood. Schizophrenia / blood. Sex Characteristics

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18382119.001).
  • [ISSN] 1423-0224
  • [Journal-full-title] Neuropsychobiology
  • [ISO-abbreviation] Neuropsychobiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


75. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Zheng R, Asano T, Nanus DM, Hayakawa M: Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma. J Urol; 2006 Oct;176(4 Pt 1):1631-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased serum leptin levels and over expression of leptin receptors are associated with the invasion and progression of renal cell carcinoma.
  • PURPOSE: Leptin, an adipocyte derived cytokine that is closely associated with obesity, was recently shown to be involved in carcinogenesis and cancer progression.
  • Because obesity is a significant risk factor for renal cell carcinoma, we investigated the link between leptin and the development of renal cell carcinoma.
  • MATERIALS AND METHODS: Associations between preoperative serum leptin levels and leptin receptor expression in tumor specimens and various clinicopathological parameters were analyzed in 57 patients with renal cell carcinoma.
  • RESULTS: Serum leptin levels were 1.2 to 16.2 ng/ml (mean 4.5).
  • Of 57 tumors 22 (38.6%) demonstrated high leptin receptor expression.
  • Serum leptin levels were significantly higher in patients with vs without tumor specimen venous invasion (p = 0.030) and higher in patients with high vs low leptin receptor expression (p = 0.019).
  • There were significant associations between high leptin receptor expression and the presence of venous invasion (p = 0.013), histological type (p = 0.0076) and regional lymph node metastasis (p = 0.047).
  • Of 42 patients with N0M0 disease those with serum leptin 5.0 ng/ml or more had significantly shorter progression-free survival than patients with lower levels (p = 0.0043).
  • Multivariate Cox proportional hazards model analysis demonstrated that higher serum leptin was an independent predictor of progression-free survival (p = 0.0406).
  • CONCLUSIONS: Leptin and leptin receptor could have a key role in the invasion of renal cell carcinoma and they could be valuable predictors of progression.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Leptin / blood. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Aged. Body Mass Index. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Receptors, Leptin. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952705.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Cell Surface; 0 / Receptors, Leptin; 0 / leptin receptor, human
  •  go-up   go-down


76. Gharote HP, Mody RN: Estimation of serum leptin in oral squamous cell carcinoma. J Oral Pathol Med; 2010 Jan;39(1):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of serum leptin in oral squamous cell carcinoma.
  • Leptin, a homologous protein of cytokine family, is found to be decreased in serum with cachexia.
  • The purpose of this study was to compare serum leptin levels of oral squamous cell carcinoma patients with that of control group and correlate it with body mass index.
  • METHOD: Serum samples of 31 oral squamous cell carcinoma patients and that of 28 healthy individuals were subjected to evaluation of serum leptin levels (ng/ml) using enzyme-linked immunosorbent assay.
  • RESULTS: A significant reduction in leptin level of oral squamous cell carcinoma patients was observed.
  • Definite correlation between body mass index and serum leptin and also between serum leptin levels of various histopathological variants of oral squamous cell carcinoma was observed.
  • CONCLUSION: The results of this study suggest that evaluation of serum leptin level can provide status of cachexia in oral squamous cell carcinoma patients.
  • [MeSH-major] Carcinoma, Squamous Cell / blood. Leptin / blood. Mouth Neoplasms / blood
  • [MeSH-minor] Adult. Age Factors. Aged. Area Under Curve. Biomarkers / blood. Body Mass Index. Cachexia / blood. Female. Humans. Male. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Sex Factors. Young Adult

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19817969.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin
  •  go-up   go-down


77. Mendoza-Núñez VM, Correa-Muñoz E, Garfias-Cruz EA, Sánchez-Rodriguez MA, Galván-Duarte RE, Retana-Ugalde R: Hyperleptinemia as a risk factor for high blood pressure in the elderly. Arch Pathol Lab Med; 2006 Feb;130(2):170-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleptinemia as a risk factor for high blood pressure in the elderly.
  • CONTEXT: Studies have demonstrated that high serum leptin levels are associated with aging.
  • We measured serum leptin levels through the radioimmunoassay method.
  • RESULTS: The elderly subjects with HBP had significantly higher leptin levels than the healthy elderly subjects (P = .02).
  • Furthermore, in female elderly subjects we observed a statistically significant correlation between systolic blood pressure and leptin (r = 0.37, P = .003), as well as systolic blood pressure and age (r = 0.29, P = .02), but not with diastolic blood pressure.
  • In male elderly subjects, there was no correlation between leptin and systolic blood pressure or leptin and diastolic blood pressure.
  • [MeSH-major] Hypertension / blood. Leptin / blood

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454556.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


78. Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z: Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One; 2010;5(7):e11859
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells.
  • BACKGROUND: The receptor tyrosine kinase like orphan receptor (ROR)-1 gene is overexpressed in chronic lymphocytic leukemia (CLL).
  • METHODOLOGY/PRINCIPAL FINDINGS: Because IL-6 induced Stat3 phosphorylation and upregulated Ror1 protein levels in MM1 cells, we used these cells as a model.
  • Finally, like STAT3-siRNA in MM1 cells, STAT3-shRNA downregulated STAT3, ROR1, and STAT3-regulated genes and Stat3 and Ror1 protein levels in CLL cells.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Receptor Tyrosine Kinase-like Orphan Receptors / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Blotting, Western. Cell Line. Cell Line, Tumor. Chromatin Immunoprecipitation. Electrophoretic Mobility Shift Assay. Genetic Vectors / genetics. Humans. Lentivirus / genetics. Mutagenesis, Site-Directed. Promoter Regions, Genetic. RNA, Small Interfering / genetics. RNA, Small Interfering / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2010 Apr 8;115(14):2852-63 [20154216.001]
  • [Cites] J Endocrinol. 2007 Apr;193(1):93-106 [17400807.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):275-8 [10700182.001]
  • [Cites] Endocrinology. 2007 Sep;148(9):4226-37 [17525119.001]
  • [Cites] Osteoporos Int. 2007 Dec;18(12):1683-92 [17619808.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11291-9 [18056455.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):396-404 [18223214.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3047-52 [18287027.001]
  • [Cites] Blood. 2008 May 1;111(9):4681-9 [18227347.001]
  • [Cites] Int J Cancer. 2008 Sep 1;123(5):1190-5 [18546292.001]
  • [Cites] Leuk Lymphoma. 2008 Jul;49(7):1360-7 [18604725.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1214-9 [18765431.001]
  • [Cites] Trends Cell Biol. 2008 Nov;18(11):536-44 [18848778.001]
  • [Cites] Blood. 2009 Jan 22;113(4):856-65 [18796623.001]
  • [Cites] Bioorg Med Chem Lett. 2009 Feb 1;19(3):606-9 [19121941.001]
  • [Cites] Int J Mol Med. 2009 Jun;23(6):763-9 [19424602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700 [19433805.001]
  • [Cites] Science. 2000 Mar 3;287(5458):1606-9 [10733430.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Immunity. 2000 Jul;13(1):15-24 [10933391.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):419-22 [10932186.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):423-6 [10932187.001]
  • [Cites] Am J Hum Genet. 2000 Oct;67(4):822-31 [10986040.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6675-88 [11053426.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6613-26 [11426647.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):466-74 [11751994.001]
  • [Cites] Science. 2002 May 31;296(5573):1653-5 [12040185.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3311-8 [12384432.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23 [14973184.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):202-6 [15327998.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26181-90 [1334494.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] Science. 1996 Aug 9;273(5276):794-7 [8670419.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9148-53 [8799169.001]
  • [Cites] EMBO J. 1996 Oct 15;15(20):5616-26 [8896455.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):3140-8 [9399961.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5206-10 [9548458.001]
  • [Cites] Hematology. 2004 Aug;9(4):279-86 [15621735.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):70-80 [15970928.001]
  • [Cites] Dev Biol. 2006 Feb 1;290(1):81-91 [16330017.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):653-8 [16423993.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1105-29 [16901035.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):273-8 [17203201.001]
  • [Cites] Int J Mol Med. 2007 Apr;19(4):699-703 [17334647.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4179-85 [19745069.001]
  • (PMID = 20686606.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / STAT3 Transcription Factor; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  • [Other-IDs] NLM/ PMC2912280
  •  go-up   go-down


79. Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL: Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer; 2008 Oct 25;114(5):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.
  • BACKGROUND: Fine-needle aspiration (FNA) of lymph nodes is commonly used to assess disease progression in patients with small lymphocytic lymphoma (SLL).
  • Although cytologic features are helpful for diagnosing typical SLL and transformed large-cell lymphoma (tLCL), SLL in accelerated phase (SLLacc) is more difficult to diagnose.
  • Additional tests are needed to identify those patients who are transforming to a higher-grade lymphoma.
  • This study evaluated the use of a multicolor fluorescence in situ hybridization (FISH) probe panel specifically designed for chronic lymphocytic leukemia (CLL)/SLL and assessed the association between FISH findings and cytologic diagnosis, proliferation index, and risk of death.
  • METHODS: FNA specimens from 50 patients (32 men and 18 women; mean age, 57 years [range, 36-77 years]) with histologically confirmed CLL and/or SLL were evaluated in this study for chromosomal abnormalities of 11q22 (ATM), 12, 13q14.3, 13q34.3 (LAMP1), and 17p13.1 (p53) by using a multiprobe FISH kit.
  • The FISH findings were compared with the cytologic diagnoses (26 SLLs, 12 SLLaccs, and 11 tLCLs), Ki-67 immunostaining, and risk of death.
  • CONCLUSIONS: FISH can be performed on FNA specimens from patients with a history of SLL/CLL.
  • Knowledge of genetic abnormalities from FNAs may be useful in deciding when and how to treat indolent or progressive SLL.
  • [MeSH-major] Biopsy, Fine-Needle. Chromosome Aberrations. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / mortality

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683215.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Ly M, Belli E, Leobon B, Kortas C, Grollmüss OE, Piot D, Planché C, Serraf A: Results of the double switch operation for congenitally corrected transposition of the great arteries. Eur J Cardiothorac Surg; 2009 May;35(5):879-83; discussion 883-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Segmental anatomy was {SLL} in all patients, dextrocardia in two patients, mesocardia in two patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346135.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Brito N, Fonseca M, Dinis I, Mirante A: Metabolic factors in obesity. J Pediatr Endocrinol Metab; 2010 Jan-Feb;23(1-2):97-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptin is an important hormone involved in the pathogenesis of obesity and has been under investigation as a risk marker for future complications. AIMS: 1.
  • To evaluate the relation between serum leptin levels and body mass index (BMI) and height.
  • 2. To compare leptin levels in obese and non-obese children.
  • 3. To evaluate the relation between leptin levels and insulin resistance index.
  • In the obese group we assessed sex, age, BMI SDS and height SDS for age and sex, and serum levels of glucose, insulin and leptin.
  • In the control group were obtained BMI SDS and height SDS for age and sex and leptin levels.
  • Leptin levels showed a positive correlation with BMI SDS (r = 0.69; p < 0.001) and height SDS (r = 0.31; p < 0.001).
  • When comparing leptin levels between obese and non-obese groups, we found a significant difference in boys (50.7 +/- 27.3 versus 7.0 +/- 6.8 ng/ml; p < 0.001) and in girls (57.6 +/- 25.5 versus 16.5 +/- 10.3 ng/ml; p < 0.001).
  • In the nonobese group, leptin levels were lower in boys.
  • Leptin showed a positive correlation with insulin resistance index in boys (r = 0.45, p = 0.05), but not in girls.
  • CONCLUSIONS: This study has confirmed a positive correlation between leptin levels and BMI SDS.
  • In obese children elevated leptin is associated with central resistance to its action.
  • The positive correlation of leptin with insulin resistance index may suggest a major role of leptin in insulin resistance.
  • [MeSH-major] Blood Glucose / metabolism. Insulin Resistance. Leptin / blood. Obesity / epidemiology. Obesity / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432812.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 0 / Leptin
  •  go-up   go-down


82. Kastenbaum HA, Khalbuss WE, Felgar RE, Stoller R, Monaco SE: The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology. Cytojournal; 2010;7:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.
  • BACKGROUND: The cytologic diagnosis of Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) often relies on finding a small lymphoid population with the characteristic immunoprofile by ancillary testing.
  • There are only a few reports of other processes identified with SLL/CLL.
  • The aim of this study was to review the fine needle aspiration (FNA) and touch prep (TP) diagnoses of SLL/CLL in order to identify any coincident entities.
  • MATERIALS AND METHODS: We retrospectively reviewed all FNA and TP cytology cases between January 2005 and May 2009 with a diagnosis of SLL/CLL to determine the presence of any coincident process.
  • Coincident entities were identified in nine cases (31%) and included seven (28%) neoplastic entities (Hodgkin lymphoma [HL], adenocarcinoma, squamous cell carcinoma, seminoma) and two (7%) non-neoplastic entities (infection and immunoglobulin containing cells).
  • Six cases (21%) suspicious for large cell transformation were also identified.
  • CONCLUSION: In our review of SLL/CLL, coincident entities were present in 31% of the cases and included a spectrum of non-neoplastic and neoplastic processes.
  • FC was the most frequently utilized ancillary test, but IHC provided important information by excluding a mantle cell lymphoma or confirming a coincident process.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976208.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2955352
  • [Keywords] NOTNLM ; Chronic lymphocytic leukemia / SLL/CLL / cytopathology / small lymphocytic lymphoma
  •  go-up   go-down


83. Chang HH, Gean PW, Chou CH, Yang YK, Tsai HC, Lu RB, Chen PS: C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients. J Clin Psychopharmacol; 2010 Oct;30(5):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C825T polymorphism of the GNB3 gene on valproate-related metabolic abnormalities in bipolar disorder patients.
  • BACKGROUND: Valproate (VPA) is a mood stabilizer for treating patients with bipolar disorder (BD).
  • RESULTS: The variation of GNB3 C825T showed an association with higher plasma total cholesterol (P = 0.037), triglyceride (P = 0.014), and leptin (P < 0.001) levels in BD patients treated with VPA.
  • After adjusting for age, sex, types of BDs, and serum concentration of VPA, the variation of GNB3 C825T remained significantly associated with the levels of serum leptin and body mass index (BMI; P < 0.001 and P = 0.030, respectively).
  • In addition, the GNB3 C825T showed significant drug-single-nucleotide polymorphism interactions with insulin levels (P = 0.033), triglyceride levels (P = 0.013), leptin levels (P = 0.013), and BMI (P = 0.018).
  • These results indicated that the T allele may be associated with lower serum leptin levels and BMI in BD patients treated with VPA.
  • [MeSH-major] Alleles. Bipolar Disorder / genetics. Bipolar Disorder / metabolism. Heterotrimeric GTP-Binding Proteins / genetics. Polymorphism, Single Nucleotide / genetics. Protein Subunits / genetics. Valproic Acid / adverse effects
  • [MeSH-minor] Adult. Body Mass Index. Female. Heterozygote Detection. Humans. Leptin / blood. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Bipolar Disorder.
  • MedlinePlus Health Information. consumer health - Bipolar Disorder.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20814328.001).
  • [ISSN] 1533-712X
  • [Journal-full-title] Journal of clinical psychopharmacology
  • [ISO-abbreviation] J Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / G-protein beta3 subunit; 0 / Leptin; 0 / Protein Subunits; 614OI1Z5WI / Valproic Acid; EC 3.6.5.1 / Heterotrimeric GTP-Binding Proteins
  •  go-up   go-down


84. Lin J, Yan GT, Gao XN, Liao J, Wang LH, Hao XH: [Distribution of leptin expression and its effect on the recovery of sepsis-induced internal disorders]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May;39(3):360-3, 417
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of leptin expression and its effect on the recovery of sepsis-induced internal disorders].
  • OBJECTIVE: To explore the distribution of leptin expression and the effect of sepsis on leptin protein and mRNA levels.
  • The mRNA expressions of leptin in those samples were determined by RT-PCR.
  • Radioimmunoassay was applied to measure serum leptin concentrations in each group at 12 h after injury, while RT-PCR was also used to detect Leptin mRNA expressions in hypothalamus, fat and lung after injury.
  • RESULTS: Leptin mRNA expressions were confirmed in all the above nine vital organs, with the highest in kidney but the lowest in testis.
  • The serum leptin level showed no significant difference between sham operation group and other four groups.
  • Compared with sham operation group, the Leptin mRNA level in CLP group decreased significantly in hypothalamus, fat and lung, while that in the other three groups showed different changes.
  • The effect of intralipid on Leptin mRNA expression was found to be a dual-direction pattern, with central stimulation but peripheral inhibition.
  • CONCLUSION: Leptin is widely expressed in multiple vital organs, and it may be a protective factor to promote recovery of sepsis-induced internal disorders.
  • [MeSH-major] Gene Expression Profiling. Leptin / physiology. Sepsis / physiopathology

  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575315.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 0 / RNA, Messenger
  •  go-up   go-down


85. Nishimura H, Akiyama T, Monobe Y, Matsubara K, Igarashi Y, Abe M, Sugihara T, Sadahira Y: Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma. Mod Pathol; 2010 Mar;23(3):439-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of sphingosine-1-phosphate receptor 1 in mantle cell lymphoma.
  • In this study, we evaluated sphingosine-1-phosphate receptor 1's suitability as a diagnostic marker for malignant lymphoma by immunostaining formalin-fixed paraffin-embedded sections using a well-defined commercial anti-sphingosine-1-phosphate receptor 1 antibody.
  • Sphingosine-1-phosphate receptor 1 was strongly expressed on the surface of small lymphocytes forming primary lymphoid follicles and in the mantle zone of secondary lymphoid follicles.
  • Microarray-based immunohistochemistry with tissue samples from 85 lymphoid malignancy cases demonstrated that sphingosine-1-phosphate receptor 1 was expressed on the surface of mantle cell lymphoma cells.
  • Strong expression was observed in all classical mantle cell lymphoma cases involving the lymph node (19 out of 19), gastrointestinal tract (10 out of 10), bone marrow (9 out of 9), and orbita (1 out of 1).
  • One aggressive variant of mantle cell lymphoma displayed a weaker membranous staining than classical mantle cell lymphoma in the lymph node and bone marrow.
  • In a cyclin D1-negative mantle cell lymphoma of the orbita, no conclusive result was obtained.
  • No cases of follicular lymphoma, marginal zone lymphoma, B lymphoblastic leukemia/lymphoma, or Burkitt's lymphoma showed any significant expression, whereas 2 out of 6 chronic lymphocytic leukemia/small lymphocytic lymphomas in bone marrow, 1 out of 3 lymphoplasmacytic lymphomas in the lymph node, and 2 out of 37 diffuse large B-cell lymphomas exhibited staining.
  • A quantitative reverse transcription polymerase chain reaction-based analysis of mantle cell lymphoma lines revealed the sphingosine-1-phosphate receptor 1 mRNA expression level to be well correlated with the results of immunocytochemistry, flow cytometry, and western blotting.
  • Thus, sphingosine-1-phosphate receptor 1 immunohistochemistry may be useful in the histological diagnosis of mantle cell lymphoma with formalin-fixed and paraffin-embedded sections.
  • [MeSH-major] Lymphoma, Mantle-Cell / metabolism. Receptors, Lysosphingolipid / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. Cell Line, Tumor. Cyclin D1 / metabolism. Female. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Middle Aged. Tissue Array Analysis

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081804.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CCND1 protein, human; 0 / Receptors, Lysosphingolipid; 0 / S1PR1 protein, human; 136601-57-5 / Cyclin D1
  •  go-up   go-down


86. Kartal O, Inal V, Baysan O, Sağlam K: [Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients]. Anadolu Kardiyol Derg; 2008 Oct;8(5):342-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum leptin levels and left ventricular hypertrophy in obese hypertensive patients].
  • [Transliterated title] Sişman hipertansif hastalarda leptin düzeyleri ve sol ventrikül hipertrofisi ile ilişkisi.
  • OBJECTIVE: Previous studies showed relation between elevated serum leptin levels (SLL) and hypertension.
  • The aim of this study was to evaluate relationship between SLL and left ventricular hypertrophy (LVH) and body mass index (BMI) in obese hypertensive patients.
  • Hypertensive patients were classified as; level-I or level-II according to JNC-VII classification and as normal weighted (18-24.99 kg/m2), over weighted (25-26.99 kg/m2) and obese (27 kg/m2 and above) according to BMI's.
  • All the patients were evaluated by echocardiography and blood samples were withdrawn for determination SLL.
  • Logistic regression analysis was applied for the evaluation of relationship between SLL and clinical variables.
  • RESULTS: Mean levels of arterial blood pressure (ABP) of total 80 patients (36 males and 44 females) was 155+/-1.1/95.1+/-0.7 mmHg and the mean age was 48.9+/-1.3 years.
  • Patients with level I hypertension (n=32) had mean ABP of 149.7+/-0.5/90.9+/-0.6 mmHg and with level-II hypertension (n=48)--mean ABP 168.5+/-1.6/102.9+/-0.9 mmHg.
  • There were no differences in LVH incidence between hypertension level groups and BMI groups (p>0.05).
  • Serum leptin levels were similar in patients with level I and level II hypertension (33.5+/-2.9 ng/ml and 37.3+/-3.6 ng/ml, respectively, p>0.05).
  • However, leptin levels were higher in obese patients as compared with normal and over weighted patients (40.9+/-3.2 ng/ml versus 28.5+/-3.6 ng/ml and 32.8+/-4.9 ng/ml, p<0.01).
  • Patients with LVH had significantly higher levels of leptin as compared with patients without LVH (51.40+/-5.1 ng/ml versus 28.30+/-4.20 ng/ml, p<0.05).
  • Logistic regression analysis demonstrated that SLL independently of blood pressure and BMI is related with LVH (OR--1.7, %95 CI--1.2-1.9, p<0.05).
  • CONCLUSION: Our study showed that elevated serum leptin levels are significantly related with LVH independently of body mass index and level of blood pressure.
  • Thus, elevated SLLs, independently of hypertension level and BMI classification, coexist with LVH.
  • Sympathetic activation or direct cardiac receptor activation or proliferative effects of leptin may be responsible for this coexistence.
  • [MeSH-major] Hypertension / blood. Hypertrophy, Left Ventricular / blood. Hypertrophy, Left Ventricular / pathology. Leptin / blood. Obesity / blood

  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anadolu Kardiyol Derg. 2008 Oct;8(5):347-9 [18849225.001]
  • (PMID = 18849224.001).
  • [ISSN] 1308-0032
  • [Journal-full-title] Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
  • [ISO-abbreviation] Anadolu Kardiyol Derg
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


87. Baseggio L, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Thieblemont C, Bryon PA, Magaud JP, Berger F, Felman P: An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement. Leuk Lymphoma; 2005 Sep;46(9):1369-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of indolent B-cell lymphoma with distinct chronic lymphocytic leukemia and marginal zone differentiation according to the site of involvement.
  • The immunological profile of lymphoproliferative disorders is usually conserved whatever the involved site, thus allowing a reliable diagnosis from peripheral blood analysis, especially in small lymphocytic lymphoma/chronic lymphocytic lymphoma (SLL/CLL).
  • Here we present a case wherein the cytology and immunophenotype of blood specimen and bone marrow argue in favor of SLL/CLL with a typical Matutes score (5/5), whereas the cyto-histology and immunophenotype of spleen specimen led to the diagnosis of splenic marginal zone B-cell lymphoma (SMZL).
  • Whereas these data suggested the presence of 2 B-cell clones, the study of the mutational status of IgVH gene in blood and spleen demonstrated the presence of a single clone, which likely developed simultaneously along two distinct ways of differentiation according to the anatomic site suggesting here the predominant role of a micro-environmental factor in cell differentiation.
  • Although rare, this kind of event must be kept in mind as a cause of discrepancies between diagnoses from different sites.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Genes, Immunoglobulin. Humans. Immunophenotyping. Male. Mutation. Splenic Neoplasms / diagnosis


88. Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Takeda S: Influencing factors of adhesion development and the efficacy of adhesion-preventing agents in patients undergoing laparoscopic myomectomy as evaluated by a second-look laparoscopy. Fertil Steril; 2008 May;89(5):1247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTION(S): Video tape recording was performed during the second-look laparoscopy (SLL) to evaluate the postoperative uterine wound adhesions and adhesions around the uterine adnexa.
  • MAIN OUTCOME MEASURE(S): Evaluation of adhesions at the uterine wound and of de novo adhesions of the uterine adnexa by SLL.
  • RESULT(S): The SLL revealed uterine surgical wound adhesions in 141 patients (37.9%) and de novo adhesions of the uterine adnexa in 33 patients (8.9%).
  • The results of analysis to determine the factors influencing the development of postoperative adhesions revealed that the diameter of the largest myoma, number of myomas, and type of adhesion-preventing agent used (except for fibrin sheath, which had no effect) influenced the incidence of postoperative adhesions at the surgical wound, but only the diameter of the largest myoma influenced the incidence of de novo adhesions of the uterine adnexa.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155700.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Fibrin Tissue Adhesive; 0 / INTERCEED
  •  go-up   go-down


89. Berger F, Traverse-Glehen A, Felman P, Callet-Bauchu E, Baseggio L, Gazzo S, Thieblemont C, Ffrench M, Magaud JP, Salles G, Coiffer B: Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity? Clin Lymphoma; 2005 Mar;5(4):220-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?
  • Waldenstrom's macroglobulinemia (WM) is considered in the World Health Organization classification as a clinical syndrome associated with monoclonal immunoglobulin (Ig) M secretion, mainly observed in patients with lymphoplasmacytic lymphoma (LPL) and occasionally with other small B-cell lymphomas.
  • Some authors consider it a rare distinct lymphoproliferative disorder with primary bone marrow infiltration and IgM monoclonal gammopathy.
  • As LPL shares important morphologic and immunophenotypic overlaps with marginal zone B-cell lymphomas (MZLs) in cases showing plasmacytic maturation, it remains unclear if they constitute unique or distinct entities.
  • Both diseases are composed of lymphocytes, lymphoplasmacytoid cells, and tumoral plasma cells with a surface (s) IgM-positive sIgD+/ cytoplasmic IgMpositive CD19+ CD20+ CD27+/ CD5 CD10 CD23 phenotype, without a specific marker.
  • Extranodal mucosa-associated lymphoid tissue (MALT) lymphoma, nodal MZL (NMZL), and splenic MZL (SMZL) are distinct entities displaying common morphologic, immunophenotypic, and genetic characteristics.
  • MALT lymphoma is clearly distinct from LPL, although bone marrow infiltration and IgM paraprotein are not rare.
  • [MeSH-major] Antigens, CD. Leukemia, Lymphocytic, Chronic, B-Cell / classification. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphoma, B-Cell / immunology. Lymphoma, B-Cell / pathology. Waldenstrom Macroglobulinemia / classification. Waldenstrom Macroglobulinemia / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794852.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Immunoglobulin M
  • [Number-of-references] 38
  •  go-up   go-down


90. Bridgeford EC, Marini RP, Feng Y, Parry NM, Rickman B, Fox JG: Gastric Helicobacter species as a cause of feline gastric lymphoma: a viable hypothesis. Vet Immunol Immunopathol; 2008 May 15;123(1-2):106-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric Helicobacter species as a cause of feline gastric lymphoma: a viable hypothesis.
  • Gastric Helicobacter spp. are associated with chronic inflammation and neoplastic transformation in humans as well as domestic and laboratory species.
  • The present study examined the association of Helicobacter heilmannii (Hhe) infection in pet cats with feline gastric mucosa associated lymphoid tissue (MALT) lymphoma.
  • Tissues were collected via gastric biopsy or at necropsy from 47 pet cats with clinical signs of gastrointestinal disease, including vomiting and inappetance, and classified as gastritis (14/47), lymphoma (31/37), or normal (2/47).
  • Tissues positive for argyrophilic organisms with Warthin-Starry stain (29/47) were assessed by fluorescent in situ hybridization (FISH) for the presence of Hhe strains 1-4 as well as with a fifth probe that detected Helicobacter salomonis, Helicobacter bizzozeronii, or Helicobacter felis.
  • Interestingly, a significant association between Hhe status and a diagnosis of lymphoblastic or lymphocytic lymphoma was observed as well in a subset of 24 Warthin-Starry positive lymphoma cases: of lymphoblastic lymphoma cases, 13/17 were positive for Hhe (p<0.05; chi(2)=4.854).
  • The association found between a positive Hhe status with the presence of feline gastric lymphoma, especially lymphoblastic lymphoma, argues for the need to conduct prospective studies to better identify the frequency and strain distribution of Hhe infection in both healthy and clinically ill cats, particularly those cats with gastric lymphoma.

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Vet Sci. 2002 Jun;3(2):123-33 [12441682.001]
  • [Cites] Aust Vet J. 2001 Jul;79(7):476-81 [11549046.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2144-51 [15131182.001]
  • [Cites] J Pathol. 2004 Aug;203(4):896-903 [15258991.001]
  • [Cites] Infect Immun. 1994 Jun;62(6):2367-74 [8188360.001]
  • [Cites] Infect Immun. 1995 Jul;63(7):2674-81 [7790084.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):217-22 [7604881.001]
  • [Cites] Am J Pathol. 1997 Jul;151(1):273-80 [9212752.001]
  • [Cites] J Clin Microbiol. 1998 Mar;36(3):634-7 [9508286.001]
  • [Cites] J Clin Microbiol. 1998 May;36(5):1366-70 [9574707.001]
  • [Cites] Scand J Gastroenterol. 1998 Aug;33(8):795-8 [9754724.001]
  • [Cites] Blood Cells Mol Dis. 2005 Jan-Feb;34(1):6-16 [15607694.001]
  • [Cites] Pathol Int. 2005 Jul;55(7):398-404 [15982214.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):797-812 [16127158.001]
  • [Cites] J Am Vet Med Assoc. 2005 Oct 1;227(7):1118-22 [16220673.001]
  • [Cites] Gut. 2006 May;55(5):616-8 [16299027.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1214-22 [17194807.001]
  • [Cites] Am J Gastroenterol. 2007 Apr;102(4):725-30 [17324128.001]
  • [Cites] Infect Immun. 2000 Feb;68(2):779-90 [10639446.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):709-21 [10666399.001]
  • [Cites] Gastroenterology. 2000 May;118(5):821-8 [10784580.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Vet Microbiol. 2001 Apr 2;79(3):253-65 [11240103.001]
  • [Cites] Vet Pathol. 2001 Mar;38(2):173-83 [11280373.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1510-6 [11283079.001]
  • [Cites] Vet Clin North Am Small Anim Pract. 2003 Sep;33(5):1083-98, vii [14552162.001]
  • (PMID = 18387674.001).
  • [ISSN] 0165-2427
  • [Journal-full-title] Veterinary immunology and immunopathology
  • [ISO-abbreviation] Vet. Immunol. Immunopathol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI037750-12; United States / NIAID NIH HHS / AI / R01 AI37750; United States / NIAID NIH HHS / AI / AI037750-12; United States / NCRR NIH HHS / RR / RR007036-20; United States / NIAID NIH HHS / AI / R01 AI037750-13; United States / NIAID NIH HHS / AI / AI037750-13; United States / NIAID NIH HHS / AI / R01 AI037750; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCRR NIH HHS / RR / T32 RR007036; United States / NCRR NIH HHS / RR / T32 RR007036-20; United States / NCRR NIH HHS / RR / T32 RR07036
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS95239; NLM/ PMC2653416
  •  go-up   go-down


91. de Larrinoa AF, del Cura J, Zabala R, Fuertes E, Bilbao F, Lopez JI: Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma. J Clin Ultrasound; 2007 Jul-Aug;35(6):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of ultrasound-guided core biopsy in the diagnosis of malignant lymphoma.
  • PURPOSE: Ultrasound-guided core needle biopsy for the diagnosis and management of malignant lymphomas is controversial and has not been accepted as an alternative to surgical biopsy.
  • METHODS: Over a 5-year period (2000-2004), ultrasound-guided core needle biopsies were performed in 102 malignant lymphomas.
  • Five diagnostic categories were considered: large B-cell lymphomas (LBCL), small B-cell lymphomas (SBCL), Hodgkin's disease (HD), T cell lymphomas, and miscellaneous.
  • SBCL (39), LBCL (36), HD (15), T cell lymphomas (5), and miscellaneous (7) [including T cell-rich B cell (2), natural killer cell (1), Burkitt's lymphoma (1), and non-Hodgkin's lymphoma of the B cell type, NOS (3)] were correctly diagnosed.
  • Three HDs, 1 natural killer cell lymphoma, 1 follicular lymphoma, and 1 LBCL were not correctly diagnosed.
  • CONCLUSIONS: Ultrasound-guided core needle biopsy is effective in the diagnosis of malignant lymphomas and can be used as the first diagnostic approach in selected clinical situations.
  • [MeSH-major] Biopsy / methods. Lymphoma / diagnosis. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / pathology. Female. Hodgkin Disease / diagnosis. Humans. Killer Cells, Natural / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Lymphoma, B-Cell / diagnosis. Lymphoma, Follicular / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, T-Cell / diagnosis. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17486566.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, Weiner GJ, Hartmann G: B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res; 2005 Feb 15;11(4):1490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
  • Synthetic CpG oligodeoxynucleotides are currently being tested in clinical trials for the therapy of different types of B cell non-Hodgkin's lymphoma.
  • However, there is only limited information on the CpG oligodeoxynucleotide sensitivity of primary malignant B cells of different non-Hodgkin's lymphoma entities.
  • Here we found that most B-cell malignancies except plasmacytoma respond to CpG oligodeoxynucleotides by up-regulating expression of costimulatory and antigen-presenting molecules, by increasing expression of CD20, and by proliferation.
  • In an in vitro analysis of 41 individual patient-derived primary tumor samples, B-cell chronic lymphocytic leukemia (B-CLL) and marginal zone lymphoma showed the strongest activation upon stimulation with CpG oligodeoxynucleotides.
  • Small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, and large cell lymphoma showed an intermediate response.
  • Although CpG oligodeoxynucleotides induced proliferation in all CpG oligodeoxynucleotide-sensitive types of B-cell malignancies, proliferation was weaker than in normal B cells and at least for B-CLL was followed by increased apoptosis.
  • In conclusion, B-cell malignancies show significant differences in their responsiveness to CpG oligodeoxynucleotides.
  • Focusing clinical studies on patients with highly CpG oligodeoxynucleotide-sensitive B-cell malignancies may improve the clinical outcome of such trials.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Oligodeoxyribonucleotides / pharmacology
  • [MeSH-minor] Adjuvants, Immunologic / pharmacology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / biosynthesis. Antigens, CD20 / immunology. Cell Proliferation / drug effects. Cell Survival / drug effects. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Membrane Glycoproteins / genetics. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / genetics. Plasmacytoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Rituximab. Time Factors. Toll-Like Receptor 9. Toll-Like Receptors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746051.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / CPG-oligonucleotide; 0 / Membrane Glycoproteins; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / TLR9 protein, human; 0 / Toll-Like Receptor 9; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


93. Xia D, Song Y, Li C, Zhang F, Wei M: The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease. Front Med China; 2007 Oct;1(4):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The change of serum leptin and its relationship with platelet membrane glycoprotein Ib in patients with coronary heart disease.
  • The aim of this paper was to investigate the change of serum leptin and its relationship with platelet membrane glycoprotein Ib (GP Ib) in patients with coronary heart disease (CHD).
  • Serum leptin was detected by enzyme linked immunosorbent assay.
  • After correcting the differences of systolic blood pressure, body mass index (BMI), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting glucose, PPBS, fasting insulin and quantitative insulin sensitive index, serum leptin level in the CHD group was significantly higher than that in the control group (P < 0.05).
  • Single factor correlative analysis revealed that serum leptin in CHD patients was negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
  • Multifactorial stepwise regression analysis showed that serum leptin in CHD patients was independently negatively correlated with the average fluorescence intensity of platelet membrane GP Ib (P < 0.05).
  • Logistic analysis demonstrated that serum leptin was independently correlated with the risk of CHD (P < 0.05).
  • The increase of serum leptin could affect blood platelet activation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Pharmacol. 2005 Apr;5(2):160-4 [15780825.001]
  • [Cites] Trends Cardiovasc Med. 2004 Jan;14(1):18-22 [14720470.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):3872-8 [15292320.001]
  • [Cites] J Cell Biol. 2001 Aug 6;154(3):485-90 [11489912.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):25096-100 [11342529.001]
  • [Cites] FASEB J. 1999 Jul;13(10):1231-8 [10385613.001]
  • [Cites] Med Hypotheses. 2006;67(1):82-6 [16500036.001]
  • [Cites] Kobe J Med Sci. 2001 Jun;47(3):141-50 [11729375.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Jan;27(1):13-8 [12532148.001]
  • [Cites] Eur Heart J. 2006 Oct;27(19):2294-9 [16543250.001]
  • [Cites] Diabetes. 1999 Sep;48(9):1787-93 [10480609.001]
  • [Cites] Circulation. 2001 Dec 18;104(25):3052-6 [11748099.001]
  • [Cites] Nature. 1998 Feb 5;391(6667):591-4 [9468137.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1998 Jun;18(6):928-33 [9633933.001]
  • [Cites] Atherosclerosis. 2007 Apr;191(2):418-26 [16712853.001]
  • [Cites] Blood. 1991 Feb 15;77(4):770-9 [1704263.001]
  • [Cites] Diabetes Care. 1998 May;21(5):782-6 [9589240.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Oct;289(4):E695-702 [15886225.001]
  • [Cites] Neurosci Lett. 2000 Oct 27;293(2):107-10 [11027845.001]
  • [Cites] Diabetes. 2003 Aug;52(8):2121-8 [12882931.001]
  • [Cites] Coron Artery Dis. 2003 Feb;14(1):65-79 [12629328.001]
  • [Cites] J Thromb Haemost. 2005 May;3(5):1042-9 [15869602.001]
  • [Cites] J Clin Invest. 1997 Jul 15;100(2):270-8 [9218503.001]
  • [Cites] Clin Exp Immunol. 2006 Mar;143(3):452-7 [16487244.001]
  • [Cites] Int J Obes Relat Metab Disord. 2001 Oct;25(10):1471-3 [11673768.001]
  • [Cites] Coron Artery Dis. 2003 Aug;14(5):357-63 [12878900.001]
  • [Cites] Diabet Med. 2005 Mar;22(3):278-85 [15717875.001]
  • [Cites] Angiology. 2006 May-Jun;57(3):267-72 [16703186.001]
  • (PMID = 24573923.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Shen XH, Tang QY, Huang J, Cai W: Vitamin E regulates adipocytokine expression in a rat model of dietary-induced obesity. Exp Biol Med (Maywood); 2010 Jan;235(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the effect of the antioxidant vitamin E (VE) on adiponectin and leptin expression in obese rats.
  • Blood and adipose tissues were then immediately collected; mRNA and protein levels of leptin and adiponectin were measured by realtime reverse transcription-polymerase chain reaction and Western blotting.
  • Biomarkers of oxidative stress, including serum levels of 8-epi-prostaglandin-F(2)alpha (8-epi-PGF(2)alpha) and glutathione peroxidase activity, were also examined.
  • Adiponectin and leptin levels were lower in the DIO group than in the control group.
  • VE intervention increased the expression of both leptin and adiponectin (P values < 0.05).
  • Association analysis showed that serum leptin levels correlated positively with body fat mass (r = 0.601, P < 0.05).
  • Both serum leptin and adiponectin levels were associated with the presence of serum 8-epi-PGF2 alpha (leptin, r = 0.513, P < 0.05; adiponectin, r = -0.422, P < 0.05).
  • Administration of VE decreases leptin and adiponectin expression in obese rats.
  • [MeSH-major] Adiponectin / blood. Adiponectin / genetics. Antioxidants / pharmacology. Leptin / blood. Leptin / genetics. Obesity / blood. Obesity / genetics. Vitamin E / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Vitamin E.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404018.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Antioxidants; 0 / Biomarkers; 0 / DNA Primers; 0 / Dietary Fats; 0 / Leptin; 0 / RNA, Messenger; 1406-18-4 / Vitamin E; 27415-26-5 / 8-epi-prostaglandin F2alpha; B7IN85G1HY / Dinoprost; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


95. Lassiter TL, Ryde IT, Levin ED, Seidler FJ, Slotkin TA: Neonatal exposure to parathion alters lipid metabolism in adulthood: Interactions with dietary fat intake and implications for neurodevelopmental deficits. Brain Res Bull; 2010 Jan 15;81(1):85-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed serum leptin and adiponectin, tumor necrosis factor-alpha (TNFalpha) in adipose tissues, and thiobarbituric acid reactive species (TBARS) in peripheral tissues and brain regions.
  • Neonatal parathion exposure uncoupled serum leptin levels from their dependence on body weight, suppressed adiponectin and elevated TNFalpha in white adipose tissue.
  • Our results are consistent with impaired fat utilization and prediabetes, as well as exposing a potential relationship between effects on fat metabolism and on synaptic function in the brain.